makalah print!
TRANSCRIPT
1
METABOLISM AND NUTRITION MODULE
B SCENARIO
PROBLEM BASED LEARNING
PRESENTED BY:
GROUP 16th
FACULTY OF MEDICINE
AIRLANGGA UNIVERSITY
3rd SEMESTER – 2010
METABOLISM AND NUTRITION MODULE
16th Group
2
METABOLISM AND NUTRITION MODULE
B SCENARIO
PROBLEM BASED LEARNING
Scenario Creator
Prof. Dr. Suhartati, dr., MS
Edhi Rianto, dr., MS
METABOLISM AND NUTRITION MODULE
16th Group
3
16th Group Members
Leader :
Shaleh Muhammad D 010911171
Members:
Muhammad Achdiar R 010911152
Filipus Michael Yofrido 010911154
Togar Erkasan Sitorus 010911155
Christopher Njotokusgito 010911157
Karin Dhia Fahmita 010911158
Dini Nur Aini 010911163
Wirawan Indra P. 010911169
Rizal Constantino Susilo 010911170
Agnes Candra Pradhita 010911172
Tutor :
dr. Subagio
METABOLISM AND NUTRITION MODULE
16th Group
4
CONTENTS
Cover ..................................................................................................................................1
Scenario Creator................................................................................................................2
Group Members ................................................................................................................3
Contents .............................................................................................................................4
Instructional Objectives ...................................................................................................5
Chapter I : 1st Tutorial .....................................................................................................6
1.1 Scenario..............................................................................................................61.2 Main Problem ....................................................................................................61.3 Keywords ..........................................................................................................61.4 Additional Information......................................................................................71.5 Early Hypothesis ...............................................................................................81.6 Early Mind Mapping .........................................................................................91.7 Learning Issue 1...............................................................................................10
Chapter II : 2nd Tutorial .................................................................................................11
2.1 Methods and Steps to Find the Information.....................................................11
2.2 The Answer of Learning Issue 1......................................................................11
2.3 Learning Issue II .............................................................................................41
Chapter III : 3rd Tutorial ................................................................................................42
3.1 The Answer of Learning Issue 1I.....................................................................42
3.2 Analysis ...........................................................................................................69
3.3 Final Hypothesis .............................................................................................76
3.4 Final Mind Mapping........................................................................................77
3.5 Group Opinion.................................................................................................79
3.6 Obstacles..........................................................................................................79
References ........................................................................................................................80
EBL & Critical Appraisal ..............................................................................................83
Appendix (Journal Appraisal) .......................................................................................91
Journal ............................................................................................................................97
METABOLISM AND NUTRITION MODULE
16th Group
INSTRUCTIONAL OBJECTIVES
5
EIGHTH MODULE
HUMAN FUNCTION MODULE
PROBLEM BASED LEARNING
After finishing this module, students of Airlangga university- School of
Medicine in third semester can explain the patophysiology of health problem
through understanding the intermediate metabolism.
METABOLISM AND NUTRITION MODULE
16th Group
A woman, came to the outpatient polyclinic with complaints often
sleepy, sometimes feel tingling in both feet.
1.1 Scenario
1.3 Key Words
1.2. Main Problem
6
CHAPTER I
FIRST TUTORIAL
Often feels sleepy
Often feels sleepy and numbness
1.3.1. Female
1.3.2. Numbness in both lower extremities
1.3.3. Outpatient treatment
1.3.4. Sleepy
METABOLISM AND NUTRITION MODULE
16th Group
1.4 Additional Information
7
1.4.1. Woman, age: 41 years old
1.4.2. Status: Married with 1 child
1.4.3. Occupation: Housewive
1.4.4. Address: Kupang Indah; Surabaya
1.4.5. She has been feeling numbness for 1 month
1.4.6. Almost every night wakes up to go to the toilet
1.4.7. Medical Record: No hypertension
Body weight has decreased 3 kg recently
1.4.8. Family Medical Record: Her father passed away due to complication
Her brother passed away in the age of 40
years old with smelly and can-not-heal
wound in his leg
1.4.9. Husband’s occupation: Private Company Officer
1.4.10. Physical Examination: Body weight: 89 kg
Height: 157 cm
Blood Pressure:120/80 mmHg
Pulse: 80 times per minute
RR: 20 times per minute
Body temperature: 37ºC
No anemic sign
No cyanotic sign
No icterus sign
Heart and Lung: Normal condition
Hepar and Spleen: cannot be sense
Abdomen Circle measurement 92 cm
No acytes sign
No extremity abnormality
METABOLISM AND NUTRITION MODULE
16th Group
1.6 Early Mind Mapping
1.5 Early Hypothesis
8
Diabetes Mellitus
Malnutrition deficiency
Anemia
Neuron disorders
Cardio-vascular disorders
Lipid metabolism disorders
Hypoxia
METABOLISM AND NUTRITION MODULE
16th Group
FINANCIALCONDITION
1.7 Learning Issue 1
9
1.7.1. What are the causes of drowsiness?
METABOLISM AND NUTRITION MODULE
16th Group
Early hypothesis:DM
Malnutrition DeficiencyNeuron Disorders
Physical Examination:
Weight 89 kgHeight 157cm
BP 120/80 mmHgPP 80 tpmRR 20 tpm
Temperature 37 ºC
Anamnesis:TinglingSleepy
Weight Loss
Supporting Exam:Hepar & Spleen normalHeart & Lung normalNo anemic, cyanotic,
icterus
Female; 41 y.o
10
1.7.2 How is the mechanism of numbness/tingling?
1.7.3 How is the patophysiology of Diabetes Mellitus?
1.7.4 What are the symptoms of Diabetes Mellitus?
1.7.5 What is normal stomach circumference of human?
1.7.6 What are the risk factors of Diabetes Mellitus?
1.7.7 What are the complications of Diabetes Mellitus?
1.7.8 What is blood gas analysis?
1.7.9 How is the normal blood glucose measurement?
1.7.10 How is the normal rate of TG?
1.7.11 How is the normal rate of Haemoglobin?
1.7.12 What is anion gap?
1.7.13 What are the symptoms of anemia?
METABOLISM AND NUTRITION MODULE
16th Group
2.1 METHODS AND STEPS TO FIND THE INFORMATION
2.2 THE ANSWERS OF LEARNING ISSUES I
11
CHAPTER II
SECOND TUTORIAL
To get the information we need, we use some sources, such as:
1. Text Books
We used text books from library, our relative’s books. We also
bought some books to get more information.
2. Internet
We got information from internet in the form of scientific journals
and articles. By typing the keywords in the search engine, we got
much information both in English and in Indonesian.
Sources in English are cited directly into this report but sources in
Indonesian are translated into English first.
2.2.1 What are the causes of drowsiness?
Having to work long hours or different shifts (nights, weekends)
Medications (tranquilizers, sleeping pills, antihistamines)
Medical conditions (such as hypothyroidism, hypercalcemia, and
hyponatremia /hypernatremia)
Not sleeping for long enough
Sleep disorders (such as sleep apnea syndrome and narcolepsy)
METABOLISM AND NUTRITION MODULE
16th Group
12
2.2.2 How is the mechanism of numbness/tingling?
Any time you remain still for a long period, particularly if you're leaning
on your arm or sitting cross-legged, you are bound to develop a pins-and-needles
sensation in one or more limbs. This feeling results from temporary nerve
compression and diminished blood flow, and it passes as soon as you move
around a bit.
Many medical conditions, however, cause a persistent tingling sensation
— usually in the hands, arms, feet, or legs — that is unrelated to posture and
unrelieved by movement. While several of these conditions originate in the
peripheral nervous system (the network of nerves branching out from the spinal
cord to the extremities), others are based primarily in different parts of the body.
In general, persistent tingling is a troubling symptom that requires a thorough
medical workup.
2.2.3 What are the patophysiologies of Diabetes Melitus?
Diabetes is a chronic metabolic disorder in which the body cannot
metabolize carbohydrates, fats, and proteins because of a lack of, or ineffective
use of, the hormone insulin. Diabetes is classified into three primary types that are
different disease entities but share the symptoms and complications of
hyperglycemia (high blood glucose). Impaired glucose tolerance, formerly known
as "borderline diabetes" is a degree of hyperglycemia that may precede type 2
diabetes.
The pathophysiology of diabetes mellitus in all forms is related to the
insulin hormone. Insulin is secreted by cells in the pancreas and is responsible for
regulating the level of glucose in the bloodstream. It also aids the body in
breaking down the glucose to be used as energy. When someone suffers from
diabetes, however, the body does not break down the glucose in the blood as a
result of abnormal insulin metabolism. This results in elevated levels of glucose in
METABOLISM AND NUTRITION MODULE
16th Group
13
the blood, which is known as hyperglycemia. When glucose levels remain high
over an extended period of time, severe complications including cardiovascular
disease, kidney damage, eye disorders, and nerve problems can occur. Diabetes
mellitus occurs in three different forms - type 1, type 2, and gestational.
I. Type 1 (previously called insulin dependent diabetes mellitus (IDDM) or juvenile onset diabetes)A. Causes
1. Genetic predisposition.
2. Environmental exposure: virus, toxin, stress.
3. Autoimmune reaction: beta-cells that produce insulin in the pancreas are
destroyed. When 80-90% of the beta-cells are destroyed, overt symptoms
occur.
B. Characteristics1. Usually occurs before 30 years of age, but can occur at any age. Peak
incidence occurs during puberty, around 10-12 years of age in girls and
12-14 years in boys.*
2. Abrupt onset of signs and symptoms of hyperglycemia: increased thirst
and hunger, frequent urination, weight loss, and fatigue.
3. Ketosis prone.
* Source: American Diabetes Association. Diabetes Facts. November, 2003.C. Treatment
1. Insulin by injection with syringes or pumps
2. Diet
3. Exercise
4. Education
5. Monitoring
II. Type 2 (previously called non-insulin-dependent diabetes mellitus, NIDDM, or adult onset diabetes)A. Causes
METABOLISM AND NUTRITION MODULE
16th Group
14
1. Insulin resistance: unable to utilize insulin that the body makes because of
cell-receptor defect; glucose is unable to be absorbed into cells for fuel.
2. Decreased insulin secretion: pancreas does not secrete enough insulin in
response to glucose levels.
3. Excess production of glucose from the liver: result of defective insulin
secretor response; dawn phenomenon (see glossary) is an example.
B. Characteristics
1. Usually occurs after 30 years of age, but is now occurring in children and
adolescents.
2. Increased prevalence in some ethnic groups, e.g., African Americans,
Hispanic/Latino, Native Americans, Asian Americans, and Pacific
Islanders.
3. Strong genetic predisposition.
4. Frequently obese.
5. Not prone to ketoacidosis until late in course or with prolonged
hyperglycemia.
6. May or may not have symptoms of hyperglycemia.
7. May also have extreme tiredness, blurred vision, delayed healing,
numbness and tingling of hands and feet, recurring yeast infection.
8. Children between the ages of 10-19 that have one or more of the following
are at an increased risk:
• Family history
• Member of certain ethnic populations listed above in B.2.
• Overweight
• Sedentary lifestyle
• Pre-puberty.
• Signs of insulin resistance or conditions associated with insulin
resistance (acanthosis nigricans [dirty-neck syndrome],
hypertension [high blood pressure], dyslipidemia [lipoproteins
inbalance], polycystic ovarian syndrome [PCOS]).
METABOLISM AND NUTRITION MODULE
16th Group
15
C. Treatment
1. Diet/weight management
2. Exercise/increase physical activity
3. Oral hypoglycemic/antihyperglycemic agents, insulin sensitizers, or
insulin
4. Education
5. Monitoring
6. Treatment of co morbid conditions (e.g., hypertension, lipid abnormalities)
III. Gestational Diabetes Mellitus (GDM)
A. Causes
1. Insulin resistance due to pregnancy
2. Genetic predisposition
B. Characteristics
1. Carbohydrate intolerance during pregnancy identified via 1-hour screen
using a 50-g oral glucose load (performed between 24th and 28th week of
gestation unless otherwise indicated). If the 1-hour screen for glucose is
>140 mg/dl (>7.8 mmol/l), a full diagnostic 100-g, 3-hour oral glucose
tolerance test (OGTT) is indicated.
C. Treatment
1. Diet: provide adequate calories without hyperglycemia or ketonemia
2. Exercise: program that does not cause fetal distress, contractions, or
hypertension (>140/90 mmHg).
3. Insulin: if unable to consistently maintain blood glucose <95 mg/dl fasting
(<5.3 mmol/ l) and <140 mg/dl (<7.8 mmol/l) 1 hour postprandial and
<120 mg/dl (<6.7 mmol/l) 2 hours postprandial.
METABOLISM AND NUTRITION MODULE
16th Group
16
D. Monitoring
1. Blood glucose: required to determine effectiveness of treatment and
possible need for insulin. Glucose should be checked fasting and 1-2 hours
postprandial.
2. Ketones: test for ketones using first morning urine sample. Presence of
ketones may indicate starvation rather than hyperglycemic ketosis.
2.2.4 What are the symptoms of Diabetes Mellitus?
Excessive thirst and increased urination
Excessive thirst and increased urination are classic diabetes signs and symptoms. When you have diabetes, excess sugar (glucose) builds up in your blood. Your kidneys are forced to work overtime to filter and absorb the excess sugar. If your kidneys can't keep up, the excess sugar is excreted into your urine along with fluids drawn from your tissues. This triggers more frequent urination, which may leave you dehydrated. As you drink more fluids to quench your thirst, you'll urinate even more.
Fatigue
You may feel fatigued. Many factors can contribute to this. They include dehydration from increased urination and your body's inability to function properly, since it's less able to use sugar for energy needs.
Weight loss
Weight fluctuations also fall under the umbrella of possible diabetes signs and symptoms. When you lose sugar through frequent urination, you also lose calories. At the same time, diabetes may keep the sugar from your food from reaching your cells — leading to constant hunger. The combined effect is potentially rapid weight loss, especially if you have type 1 diabetes.
Blurred vision
Diabetes symptoms sometimes involve your vision. High levels of blood sugar pull fluid from your tissues, including the lenses of your eyes. This affects your ability to focus.
Left untreated, diabetes can cause new blood vessels to form in your retina — the back part of your eye — as well as damage established vessels. For most people, these early changes do not cause vision problems. However, if these changes progress undetected, they can lead to vision loss and blindness.
METABOLISM AND NUTRITION MODULE
16th Group
17
Slow-healing sores or frequent infections
Doctors and people with diabetes have observed that infections seem more common if you have diabetes. Research in this area, however, has not proved whether this is entirely true, nor why. It may be that high levels of blood sugar impair your body's natural healing process and your ability to fight infections. For women, bladder and vaginal infections are especially common.
Tingling hands and feet
Excess sugar in your blood can lead to nerve damage. You may notice tingling and loss of sensation in your hands and feet, as well as burning pain in your arms, hands, legs and feet.
Red, swollen, tender gums
Diabetes may weaken your ability to fight germs, which increases the risk of infection in your gums and in the bones that hold your teeth in place. Your gums may pull away from your teeth, your teeth may become loose, or you may develop sores or pockets of pus in your gums — especially if you have a gum infection before diabetes develops.
2.2.5 What is normal stomach circumference of human?
To determine whether suffering abdominal obesity or not, the people of
Indonesia have the ideal waist size. Usually, women's waist size 90 inches biggest
meter and men's 80 inch meter. If more than that, they sign congested hormone
bad fats in the stomach. This will trigger the spread of various diseases metabolic
disorders.
If someone has abdominal circumference more than the normal number,
then it could be said he was experiencing abdominal obesity. What causes
obesity? It is said that there are two factors causing the genetic and lifestyle
factors. However, more cases of abdominal fat due to diet and an increasingly
unbalanced motion.
In fact, unhealthy lifestyle diseases (metabolic syndrome), stage 1 has
been ongoing since early 1990, particularly in urban areas. Since then the
Indonesian people begin to experience obesity. Especially since the fast-food
restaurants to grow and increasingly giving kemudahkan for people to eat all the
time. Meanwhile, the pattern of motion (sports) in the stomach the less. Whereas
METABOLISM AND NUTRITION MODULE
16th Group
18
most high mobility of fat in the abdomen and the nature of fat is more dangerous
than the fat in the thighs or in other organs.
Also explained that the fat can not be removed through liposuction,
because the fat inside the abdomen, rather than under a layer of skin. The
hormone estrogen source of fat in the thighs, the center of power, and bearing, on
the contrary in the stomach, the hormone is more dangerous, and in abdominal fat,
there are a lot of the mobility of free fatty acids to the liver and
muscles. Furthermore, it will affect the fatty acid metabolism and pancreatic
work.
2.2.6 What are the risk factors of Diabetes Mellitus?
You have a higher risk for diabetes if you have any of the following:
Age greater than 45 years
Diabetes during a previous pregnancy
Excess body weight (especially around the waist)
Family history of diabetes
Given birth to a baby weighing more than 9 pounds
HDL cholesterol under 35 mg/dL
High blood levels of triglycerides, a type of fat molecule (250 mg/dL or
more)
High blood pressure (greater than or equal to 140/90 mmHg)
Impaired glucose tolerance
Low activity level (exercising less than 3 times a week)
Metabolic syndrome
Polycystic ovarian syndrome
A condition called acanthosis nigricans, which causes dark, thickened skin
around the neck or armpits
Persons from certain ethnic groups, including African Americans,
Hispanic Americans, Asian Americans, and Native Americans, have a higher risk
for diabetes.
METABOLISM AND NUTRITION MODULE
16th Group
19
Everyone over 45 should have a blood sugar (glucose) test at least every 3
years. Regular testing of blood sugar levels should begin at a younger age, and be
performed more often if you are at higher risk for diabetes. (MedlinePlus, 2010)
2.2.7 What are the complications of Diabetes Mellitus?
Without proper management it can lead to various complications such as
cardiovascular disease, kidney failure, blindness and nerve damage. Short-term
complications:
Low blood sugar (hypoglycaemia)
A person who takes insulin is going to face the problem of their blood
sugar falling too low at some point (because they have overestimated the
insulin they need, have exercised more than anticipated or have not eaten
enough). Hypoglycaemia can be corrected rapidly by eating some sugar. If
it is not corrected it can lead to the person losing consciousness.
It is important that the person with diabetes recognises the signs of
hypoglycaemia.
Ketoacidosis
When the body breaks down fats, acidic waste products called ketones are
produced. The body cannot tolerate large amounts of ketones and will try
to get rid of them through the urine. However, the body cannot release all
the ketones and they build up in your blood, causing ketoacidosis.
Ketoacidosis is a severe condition caused by lack of insulin. It mainly
affects people with type 1 diabetes.
Lactic acidosis
Lactic acidosis is the build up of lactic acid in the body. Cells make lactic
acid when they use glucose for energy. If too much lactic acid stays in the
body, the balance tips and the person begins to feel ill. Lactic acidosis is
rare and mainly affects people with type 2 diabetes.
Bacterial/fungal infections
METABOLISM AND NUTRITION MODULE
16th Group
20
People with diabetes are more prone to bacterial and fungal infections.
Bacterial infections include sties and boils. Fungal infections include
athlete’s foot, ringworm and vaginal infections.
Long-term complications:
Eye disease (retinopathy)
Eye disease, or retinopathy, is the leading cause of blindness and visual
impairment in adults in developed societies. About 2% of all people who
have had diabetes for 15 years become blind, while about 10% develop a
severe visual impairment.
IDF fact sheet on diabetes and eye disease
Kidney disease (nephropathy)
Diabetes is the leading cause of kidney disease (nephropathy). About one
third of all people with diabetes develop kidney disease and approximately
20% of people with type 1 diabetes develop kidney failure.
IDF fact sheet on diabetes and kidney disease
Nerve disease (neuropathy)
Diabetic nerve disease, or neuropathy affects at least half of all people
with diabetes. There are different types of nerve disease which can result
in a loss of sensation in the feet or in some cases the hands, pain in the foot
and problems with the functioning of different parts of the body including
the heart, the eye, the stomach, the bladder and the penis. A lack of
sensation in the feet can lead to people with diabetes injuring their feet
without realising it. These injuries can lead to ulcers and possibly
amputation.
Diseases of the circulatory system
Disease of the circulatory system, or cardiovascular disease, accounts for
75% of all deaths among people with diabetes of European origin. In the
USA, corony heart disease is present in between 8% and 20% of people
with diabetes over 45 years of age. Their risk of heart disease is 2-4 times
METABOLISM AND NUTRITION MODULE
16th Group
21
higher than those who do not have diabetes. It is the main cause of
disability and death for people with type 2 diabetes in industrialized
countries.
IDF fact sheet on diabetes and cardiovascular disease
Amputation
Diabetes is the most common cause of amputation that is not the result of
an accident. People with diabetes are 15 to 40 times more likely to require
lower-limb amputation compared to the general population. (International
Diabetes Federation, 2010)
2.2.8 What is the blood gas analysis?
Blood Gases, Arterial (ABG)—Blood Norm.
Must be corrected for body temperature.
SI Units
pH
Adults 7.35–7.45 7.35–7.45
Panic values ≤7.2 and >7.6 ≤7.2 and >7.6
Children
Birth to 2 months 7.32–7.49 7.32–7.49
2 months to 2 years 7.34–7.46 7.34–7.46
>2 years 7.35–7.45 7.35–7.45
PaCO2 35–40 mm Hg 4.7–5.3 kPa
Panic values <20 mm Hg <2.7 kPa
>70 mm Hg >9.4 kPa
PaO2 80–100 mm Hg 10.7–13.3 kPa
Panic values <40 mm Hg <5.3 kPa
HCO3- 22–31 mEq/L 22–31 mmol/L
METABOLISM AND NUTRITION MODULE
16th Group
22
SI Units
Panic values <10 mEq/L <10 mmol/L
>40 mEq/L >40 mmol/L
O2 Saturation 96%–100% 0.96–1.00
Panic value <60% <0.60
Oxyhemoglobin Dissociation Curve No shift
Increased pH.
Alkali ingestion, Cushing's disease, diarrhea, fever, high altitude,
hyperventilation, hysteria, intestinal obstruction (pyloric, duodenal), metabolic
alkalosis, peptic ulcer therapy, renal disease, respiratory alkalosis, salicylate
intoxication, and vomiting (excessive). Drugs include sodium bicarbonate.
Increased PaCO2.
Acute intermittent porphyria, aminoglycoside toxicity, asthma (late stage), brain
death, coarctation of the aorta, congestive heart failure, electrolyte disturbance
(severe), emphysema, empyema, hyaline membrane disease, hyperemesis,
hypothyroidism (severe), hypoventilation (alveolar), metabolic alkalosis, near
drowning, pleural effusion, pleurisy, pneumonia, pneumothorax, poisoning,
pulmonary edema, pulmonary infection, renal disorders, respiratory acidosis,
respiratory failure, shock, tetralogy of Fallot, transposition of the great vessels,
and vomiting. Drugs include aldosterone, ethacrynic acid, metolazone,
prednisone, sodium bicarbonate, and thiazides.
Increased PaO2.
Hyperbaric oxygenation and hyperventilation.
Increased HCO3-.
Anoxia, metabolic alkalosis, and respiratory acidosis.
Increased O2 Saturation.
METABOLISM AND NUTRITION MODULE
16th Group
23
High altitudes, hypocapnia, hypothermia, increased cardiac output, hyperbaric
oxygenation, increased oxygen affinity for hemoglobin, oxygen therapy, positive
end-expiratory pressure (PEEP) added to mechanical ventilation, respiratory
alkalosis.
Decreased pH.
Addison's disease, asthma, cardiac disease, diabetic ketoacidosis, diarrhea,
emphysema, dysrhythmias, hepatic disease, hypercapnia, hypoventilation,
malignant hyperthermia, metabolic acidosis, myocardial infarction, nephritis,
nephrosis, pneumonia, pulmonary edema, pulmonary embolism, pulmonary
infection, pulmonary malignancy, pulmonary obstructive disease, renal disease,
respiratory acidosis (also caused by large volumes of lactated Ringer's),
respiratory failure, sepsis, and shock.
Decreased PaCO2.
Dysrhythmias, asthma (early stage), diabetic ketoacidosis, diabetes mellitus,
fever, high altitude, hyperventilation, metabolic acidosis, respiratory alkalosis,
and salicylate intoxication. Drugs include acetazolamide, dimercaprol, methicillin
sodium, nitrofurantoin, nitrofurantoin sodium, tetracycline, and triamterene.
Decreased PaO2.
Acute respiratory distress syndrome, anoxia, anesthesia, aortic valve stenosis,
arteriovenous shunt, asthma, atelectasis, atrial septal defect, berylliosis, carbon
monoxide poisoning, cerebrovascular accident, coarctation of the aorta,
emphysema, flail chest, Hamman-Rich syndrome, head injury, hyaline membrane
disease, hypercapnia, hypoventilation, lung resection, lymphangitic
carcinomatosis, near drowning, phrenic nerve paralysis, pickwickian syndrome,
pain causing restricted diaphragmatic breathing, pleural effusion, pneumonia,
pneumothorax, poisoning, poliomyelitis (acute), pulmonary adenomatosis,
pulmonary embolism, pulmonary infection, pulmonary hemangioma, pulmonic
stenosis, respiratory failure, sarcoidosis, shock, smoke inhalation, status
METABOLISM AND NUTRITION MODULE
16th Group
24
epilepticus, tetanus, transposition of the great vessels, tricuspid atresia, and
ventricular septal defect.
Decreased HCO3-.
Hypocapnia, metabolic acidosis, and respiratory alkalosis.
Decreased O2 Saturation.
Acute respiratory distress syndrome, anesthesia, anoxia, anorexia, aortic valve
stenosis, arteriovenous shunt, asthma, atelectasis, atrial septal defect, berylliosis,
carbon monoxide poisoning, cerebrovascular accident, coarctation of the aorta,
congenital heart defects, decreased cardiac output, decreased oxygen affinity for
hemoglobin, emphysema, fever, flail chest, Hamman-Rich syndrome, head injury,
hyaline membrane disease, hypercapnia, hypoventilation, hypoxia, lung resection,
lymphangitic carcinomatosis, near drowning, phrenic nerve paralysis, pickwickian
syndrome, pain causing restricted diaphragmatic breathing, pleural effusion,
pneumonia, pneumothorax, poisoning, poliomyelitis (acute), pulmonary
adenomatosis, pulmonary embolism, pulmonary infection, pulmonary
hemangioma, pulmonic stenosis, respiratory acidosis, respiratory failure,
sarcoidosis, shock, smoke inhalation, status epilepticus, tetanus, transposition of
the great vessels, tricuspid atresia, and ventricular septal defect.
Oxyhemoglobin Dissociation Curve.
See diagram.
Shift to Left.
2,3-DPG deficiency, high altitude, hypocapnia, hypothermia, and respiratory
alkalosis.
Shift to Right.
Cluster headaches, emphysema, fever, hypercapnia, increased production of 2,3-
DPG, and respiratory acidosis.
METABOLISM AND NUTRITION MODULE
16th Group
25
Description.
The arterial blood gas test measures the dissolved oxygen and carbon dioxide in
the arterial blood and reveals the acid-base state and how well the oxygen is being
carried to the body. The pH is the measurement of free H+ ion concentration in
circulating blood. Intracellular metabolism results in the continuous production of
hydrogen ions, which are buffered as either an acid (HCO3-) or a base (H2CO3).
The body demands that pH remain constant. The kidneys and lungs regulate pH
by preserving the ratio of acid to base. Any alteration in the ratio between
bicarbonate and carbonic acid will cause a reciprocal change in release or uptake
of free H+, thereby altering pH value. Significant deviations in pH can be life
threatening. Both bicarbonate (HCO3-) and carbonic acid (H2CO3) are components
of the body's acid-base system that influence pH. The partial pressure of carbon
dioxide (pCO2, PaCO2) is the amount of carbon dioxide in the blood based on the
pressure it exerts in the bloodstream and represents the degree of alveolar
ventilation occurring. When pH decreases, more CO2 dissociates from carbonic
acid and is exhaled through the lungs, counteracting the pH reduction and
increasing the breathing rate. The partial pressure of oxygen (pO2, PaO2) is the
amount of oxygen dissolved in plasma and represents the status of alveolar gas
exchange with inspired air. Oxygen saturation (O2Sat) is the amount of oxygen
actually bound to hemoglobin (as a percentage of the maximum amount that could
be bound) and available for transport throughout the body. SaO2 applies to arterial
hemoglobin saturation:
The oxyhemoglobin dissociation curve represents the affinity of hemoglobin for
oxygen by demonstrating the normal levels of arterial oxygen saturation (O2Sat,
SaO2) of hemoglobin at varying partial pressures of oxygen. P-50 is the partial
pressure of oxygen at which the given hemoglobin sample is 50% saturated. The
Hem-O-Scan machine analyzes and plots the hemoglobin-oxygen dissociation on
a curve. When the curve is shifted to the left, more oxygen is delivered to the
tissues for a given partial pressure of oxygen; when the shift is to the right, less
oxygen is delivered to the tissues. Generally, decreased oxygen saturation to less
METABOLISM AND NUTRITION MODULE
16th Group
26
than 90%–92% must be addressed by thorough assessment of the client and
clinical status.
Blood Gases, Venous—Blood Norm.
Must be corrected for body temperature.
SI Units
pH 7.32–7.43 7.32–7.43
Panic value <7.2 or >7.6 <7.2 or >7.6
pCO2 35–45 mm Hg 4.6–6.0 kPa
pO2 20–49 mm Hg 2.6–6.5 kPa
HCO3- 17–23 mEq/L 17–23 mmol/L
Panic values <10 mEq/L <10 mmol/L
>40 mEq/L >40 mEq/L
O2 Saturation 60%–80% 0.60–0.80
Increased pH.
See Blood gases, Arterial—Blood .
Increased pCO2.
See Blood gases, Arterial—Blood .
Increased pO2.
Interpretation of oxygen levels is not appropriate on venous blood specimens.
Increased HCO3-.
See Blood gases, Arterial—Blood .
Increased O2 Saturation.
Interpretation of oxygen saturation is not appropriate on venous blood specimens.
METABOLISM AND NUTRITION MODULE
16th Group
27
Decreased pH.
See Blood gases, Arterial—Blood .
Decreased pCO2.
See Blood gases, Arterial—Blood .
Decreased pO2.
Interpretation of oxygen levels is not appropriate on venous blood specimens.
Decreased HCO3-.
See Blood gases, Arterial—Blood .
Decreased O2 Saturation.
Interpretation of oxygen saturation is not appropriate on venous blood specimens.
Description.
A method for assessing acid-base status and for cellular hypoxia without
performing an arterial puncture. Venous blood gases may be used in situations
where assessment of oxygenation is unnecessary. (See Blood gases, Arterial—
Blood for complete descriptions of the test components.)
Blood Gases, Capillary—Blood Norm.
Must be corrected for body temperature.
SI Units
pH
Adults 7.35–7.45 7.35–7.45
Panic values <7.2 or >7.6 <7.2 or >7.6
Children (arterialized capillary sample)
Birth to 2 months 7.32–7.49 7.32–7.49
2 months to 2 years 7.34–7.46 7.34–7.46
METABOLISM AND NUTRITION MODULE
16th Group
28
SI Units
>2 years 7.35–7.45 7.35–7.45
pCO2 26.4–41.2 mm Hg 3.5–5.4 kPa
Panic values <20 mm Hg <2.7 kPa
>70 mm Hg >9.4 kPa
pO2 75–100 mm Hg 10.0–13.3 kPa
Panic values <40 mm Hg <5.3 kPa
HCO3- 22–26 mEq/L 22–26 mmol/L
Panic values <10 mEq/L <10 mmol/L
>40 mEq/L >40 mmol/L
O2 Saturation 96%–100% 0.96–1.00
Panic value <60% <0.60
Increased pH.
See Blood gases, Arterial—Blood .
Increased pCO2.
See Blood gases, Arterial—Blood .
Increased pO2.
See Blood gases, Arterial—Blood .
Increased HCO3-.
See Blood gases, Arterial—Blood .
Increased O2 Saturation.
See Blood gases, Arterial—Blood .
Decreased pH.
See Blood gases, Arterial—Blood .
Decreased pCO2.
METABOLISM AND NUTRITION MODULE
16th Group
29
See Blood gases, Arterial—Blood .
Decreased pO2.
Capillary pO2 interpretation is limited to assessment for hypoxia.
Decreased HCO3-.
See Blood gases, Arterial—Blood .
Decreased O2 Saturation.
See Blood gases, Arterial—Blood .
Description.
A method for determining acid-base status from a heel stick for capillary blood.
Used mostly in infants to assess pH and pCO2. (See Blood gases, Arterial , for
complete description of the test components.) (Chernecky & Berger, 2008)
2.2.9 How is the normal blood glucose measurement?
Glucose—Blood Norm.
Dependent on time and content of last meal. In normal clients, glucose levels return to the fasting level (given in these norms) within 2 hours after the last meal.
SI Units
Whole Blood
Adults 60–89 mg/dL 3.3–4.9 mmol/L
>60 years 68–98 mg/dL 3.8–5.4 mmol/L
Children
Cord blood 38–82 mg/dL 2.1–4.6 mmol/L
Premature infant 17–51 mg/dL 0.9–2.8 mmol/L
Neonate 25–51 mg/dL 1.4–2.8 mmol/L
Newborn to 24 hours 34–51 mg/dL 1.9–2.8 mmol/L
Newborn >24 hours 42–68 mg/dL 2.3–3.8 mmol/L
METABOLISM AND NUTRITION MODULE
16th Group
30
SI Units
Child 51–85 mg/dL 2.8–4.7 mmol/L
Serum
Adults 65–100 mg/dL 3.6–5.5 mmol/L
>60 years 80–115 mg/dL 4.4–6.4 mmol/L
Children
Cord blood 45–96 mg/dL 2.5–5.3 mmol/L
Premature infants 20–60 mg/dL 1.1–3.3 mmol/L
Neonates 30–60 mg/dL 1.7–3.3 mmol/L
Newborn to 24 hours 40–60 mg/dL 2.2–3.3 mmol/L
Newborn >24 hours 50–80 mg/dL 2.8–4.4 mmol/L
Child 60–100 mg/dL 3.3–5.5 mmol/L
NOTE: Whole-blood glucose values are about 15% less than serum glucose values because of greater dilution.
Panic Levels
Adults <40 mg/dL or >700 mg/dL
<2.2 mmol/L or >38.6 mmol/L
Neonates <30 mg/dL or >300 mg/dL
<1.6 mmol/L >16.0 mmol/L
Increased.
Acromegaly, anesthesia, burns, carbon monoxide poisoning, cerebrovascular
accident, convulsions, Cushing's disease, Cushing's syndrome, cystic fibrosis,
diabetes mellitus, eclampsia, encephalitis, erectile dysfunction, gigantism,
hemochromatosis, hemorrhage, hyperosmolar hyperglycemic nonketotic coma
(HHNK), hyperthyroidism, hyperpituitarism, hyperadrenalism, hypertension,
hypervitaminosis A (chronic), infections, injury, malnutrition (chronic),
meningitis, myocardial infarction, obesity, pancreatic carcinoma, pancreatic
insufficiency, pancreatitis (chronic), pheochromocytoma, pituitary adenoma,
pregnancy, shock, subarachnoid hemorrhage, stress, trauma, and Wernicke's
METABOLISM AND NUTRITION MODULE
16th Group
31
encephalopathy. Drugs include anabolic steroids, androgens, arginine, ascorbic
acid, asparaginase, aspirin, atenolol, baclofen, benzodiazepines, bisacodyl
(prolonged use), chlorpromazine, chlorthalidone, cimetidine, clonidine,
corticosteroids, corticotropin, dextran, dextrothyroxine, diazoxide, disopyramide
phosphate, epinephrine, epinephrine bitartrate, epinephrine borate, epinephrine
hydrochloride, estrogens, ethacrynic acid, furosemide, glucose infusions,
haloperidol, imipramine, isoproterenol hydrochloride, heparin calcium, heparin
sodium, hydralazine hydrochloride, hydrochlorothiazide, indomethacin, isoniazid,
levodopa, levothyroxine sodium/T4, lithium carbonate, magnesium hydroxide
(prolonged high doses), meperidine, mercaptopurine, methimazole, methyldopa,
methyldopate (hydrochloride), metronidazole, nalidixic acid, niacin, nicotine,
nicotinic acid, oral contraceptives, oxazepam, p-aminosalicyclic acid,
phenolphthalein, phenytoin, phenytoin sodium, progestins, promethazine
hydrochloride, propranolol (in diabetic clients), propylthiouracil, protease
inhibitors, reserpine, rifampin, risperidone, ritodrine hydrochloride, sildenafil,
terbutaline sulfate, tetracyclines, thiazides/thiazide diuretics, thyroglobulin,
thyroid medications, tolbutamide (SMA methodology), and triamterene.
Decreased.
Addison's disease, adrenal medulla unresponsiveness, alcoholism, carcinoma
(adrenal gland, stomach, fibrosarcoma), cirrhosis, cretinism, diabetes mellitus
(early), dumping syndrome, exercise, fever, Forbes' disease (type III glycogen
deposition disease), fructose intolerance, galactosemia, glucagon deficiency,
hepatic phosphorylase deficiency (type VI glycogen storage disease), hepatitis,
hyperinsulinemia, hypopituitarism, hypothermia, hypothyroidism, infant of
diabetic mother, insulin overdose (factitious hypoglycemia), insulinoma,
kwashiorkor, leucine sensitivity, malnutrition, maple syrup urine disease, muscle
phosphofructokinase deficiency (type VII glycogen storage disease), myxedema,
pancreatic islet cell tumor, pancreatitis, postoperatively (after gastrectomy or
gastroenterostomy), postprandial hypoglycemia, Reye's syndrome, Simmonds'
disease, vomiting, von Gierke's disease (type I glycogen storage disease),
METABOLISM AND NUTRITION MODULE
16th Group
32
Waterhouse-Friderichsen syndrome, and Zetterstrom syndrome. Drugs include
acetaminophen, allopurinol, amphetamines, aspirin, atenolol, beta-adrenergic
blockers, caffeine, cerivastatin, chlorpropamide, clofibrate, edetate disodium,
ethyl alcohol (ethanol), gatifloxacin, guanethidine sulfate, isoniazid, insulin,
isocarboxazid, marijuana, nitrazepam, oral hypoglycemic agents, p-aminosalicylic
acid, pargyline hydrochloride, phenacetin, phenazopyridine, phenelzine sulfate,
phenformin, propranolol (in diabetics), tetracyclines, theophylline, and
tranylcypromine sulfate. Herbs or natural remedies include zhi mu (‘know-
mother,' Anemarrhena asphodeloides, an herb) and shi gao (‘stone-plaster,'
calcium sulfate, gypsum) taken in combination; xuan shen (‘black ginseng,'
Scrophularia ningpoensis, figwort) and cang zhu (‘green-shu/zhu herb,'
Atractylodes lancea, var. ovata) taken in combination; shan yao (‘mountain-
medicine,' Dioscorea batatas, potato yam) and huang qi (‘yellow-old 60,'
Astragalus reflexistipulus, or A. hoantchy, yellow vetch) taken in combination;
and karela (Momordica charantia, balsam apple) taken in combination with
chlorpropamide. Herbs or natural remedies include teas (decoctions, infusions)
containing chromium, karela, ginseng, guar gum, meshasringi (Gymnema
sylvestre, mesha shringi, Indian milkweed vine), methi (fenugreek leaves),
syzigium cumini (jamun), tundika (Coccinia indica).
Description.
Glucose is a monosaccharide found naturally occurring in fruits. It is also formed
from the digestion of carbohydrates and the conversion of glycogen by the liver
and is the body's main source of cellular energy. Glucose is essential for brain and
erythrocyte function. Excess glucose is stored as glycogen in the liver and muscle
cells. Hormones influencing glucose metabolism include insulin, glucagon,
thyroxine, somatostatin, cortisol, and epinephrine. Fasting glucose levels are used
to help diagnose diabetes mellitus and hypoglycemia. A randomly timed test for
glucose is usually performed for routine screening and nonspecific evaluation of
carbohydrate metabolism. The American Diabetes Association criteria for
METABOLISM AND NUTRITION MODULE
16th Group
33
diagnosis of diabetes mellitus include a fasting plasma glucose level of >126
mg/dL (7 mmol/L).
Glucose, 2-Hour Postprandial—Serum Norm.
SI Units
Newborn to 50 years 65–140 mg/dL
3.6–7.7 mmol/L
50–60 years 65–150 mg/dL
3.6–8.3 mmol/L
>60 years 65–160 mg/dL
3.6–8.8 mmol/L
American Diabetes Association diagnosis of diabetes (after 75-g glucose load)
>200 mg/dL
>11 mmol/L
Usage.
Screening for diabetes mellitus and assessing control of hyperglycemia.
Increased.
Acromegaly, anoxia, anxiety, brain tumor, cirrhosis, convulsive disorders,
Cushing's disease, Cushing's syndromea, diabetes mellitus, dumping syndrome
(after gastrectomy), hepatic disease (chronic), hyperlipoproteinemia,
hyperthyroidism, infarction (myocardial, cerebral), lipoproteinemias, malnutrition,
malignancy, nephrotic syndrome, pancreatitis, pheochromocytoma, preeclampsia,
pregnancy, sepsis, and stress (physical, emotional). Drugs include those discussed
under Glucose—Blood.
Decreased.
METABOLISM AND NUTRITION MODULE
16th Group
34
Addison's disease, adrenal insufficiency, anterior pituitary insufficiency,
congenital adrenal hyperplasia, hepatic insufficiency, hyperinsulinism,
hypoglycemia, hypopituitarism, hypothyroidism, insulinoma, islet cell adenoma,
malabsorption syndrome, myxedema, steatorrhea, and von Gierke's disease. Drugs
include those discussed under Glucose—Blood.
Description.
The 2-hour postprandial glucose test is the measurement of serum glucose level 2
hours from the beginning of a meal containing a specific amount of carbohydrate.
In normal clients, glucose should return to fasting levels within 2 hours after the
ingestion of the test meal. (Chernecky & Berger, 2008)
2.2.10 How is the normal rate of TG?
Triglycerides—Blood Norm.
Serum Values SI Units
Adult Females
20–29 years 10–100 mg/dL 0.11–1.13 mmol/L
30–39 years 10–110 mg/dL 0.11–1.24 mmol/L
40–49 years 10–122 mg/dL 0.11–1.38 mmol/L
50–59 years 10–134 mg/dL 0.11–1.51 mmol/L
>59 years 10–147 mg/dL 0.11–1.66 mmol/L
Adult Males
20–29 years 10–157 mg/dL 0.11–1.77 mmol/L
30–39 years 10–182 mg/dL 0.11–2.05 mmol/L
40–49 years 10–193 mg/dL 0.11–2.18 mmol/L
50–59 years 10–197 mg/dL 0.11–2.22 mmol/L
METABOLISM AND NUTRITION MODULE
16th Group
35
Serum Values SI Units
>59 years 10–199 mg/dL 0.11–2.24 mmol/L
Children
Female: 1–19 years 10–121 mg/dL 0.11–1.36 mmol/L
Male: 1–19 years 10–103 mg/dL 0.11–1.16 mmol/L
NOTE: Plasma values are lower by about 3%.
Classification of Triglyceride Levels
Borderline high 200–400 mg/dL 2.3–4.5 mmol/L
High 400–1000 mg/dL 4.5–11.3 mmol/L
Very high >1000 mg/dL >11.3 mmol/L
Increased.
Alcoholism, aortic aneurysm, aortitis, arteriosclerosis, diabetes mellitus, diet
(recent high-carbohydrate, prolonged high-fat), familial hypertriglyceridemia, fat
embolism, glycogen storage diseases, gout, hepatic cholesterol ester storage
disease, hypercholesterolemia, hyperlipoproteinemia, hypothyroidism, metabolic
syndrome (>150 mg/dL), myocardial infarction (for up to 1 year), myxedema,
nephrotic syndrome, obesity, pancreatitis, pregnancy, renal insufficiency
(chronic), starvation (early), stress, Tangier disease, and von Gierke's disease.
Tobacco use. Drugs include cholestyramine, corticosteroids, estrogens, ethyl
alcohol (ethanol), miconazole (intravenous), oral contraceptives, and
spironolactone.
Decreased.
Abetalipoproteinemia, acanthocytosis, cirrhosis (portal), chronic obstructive
pulmonary disease, hyperalimentation, hyperthyroidism, malabsorption, and
malnutrition. Drugs include ascorbic acid, asparaginase, clofibrate,
dextrothyroxine, gemfibrozil, heparin, lovastatin, metformin, niacin, phenformin,
METABOLISM AND NUTRITION MODULE
16th Group
36
pravastatin, and sulfonylureas. Herbal or natural remedies include Cordyceps
sinensis, garlic (aged extract taken over time), and soy.
Description.
Also known as “fat,” triglyceride is a compound consisting of fatty acid or
glycerol ester that constitutes a major part (up to 70%) of very-low-density
lipoproteins (VLDLs) and a small part (<10%) of low-density lipoproteins (LDLs)
in fasting serum samples. Dietary triglycerides are carried as part of chylomicrons
through the lymphatic system and bloodstream to adipose tissue, where they are
released for storage. Triglycerides are also synthesized in the liver from fatty
acids and from protein and glucose above the body's current needs and then stored
in adipose tissue. They may be later retrieved and formed into glucose through
gluconeogenesis when needed by the body. Triglyceride levels are taken into
consideration with total cholesterol, high-density lipoprotein cholesterol, and
chylomicron levels when categorizing a client's serum into lipoprotein phenotypes
that represent genetic lipoprotein abnormal-ities. Treatments differ for the
different phenotypes. (Chernecky & Berger, 2008)
2.2.11 How is the normal rate of Haemoglobin?
Hemoglobin (Hb, Hgb) Norm.
SI Units
Females 12–16 g/dL 7.45–9.90 mmol/L
Pregnant 10–15 g/dL 6.3–9.9 mmol/L
Males 13.6–18.0 g/dL 8.44–11.17 mmol/L
Children
Neonates 14–27 g/dL 8.69–16.76 mmol/L
3 months 10–17 g/dL 6.21–10.55 mmol/L
1–2 years 9–15 g/dL 5.58–9.31 mmol/L
METABOLISM AND NUTRITION MODULE
16th Group
37
SI Units
6–10 years 11–16 g/dL 6.82–9.92 mmol/L
Panic Levels <5 g/dL <3.10 mmol/L
>20 g/dL >12.41 mmol/L
Increased.
Burns (severe), congestive heart failure, chronic obstructive pulmonary disease
(COPD), dehydration, diarrhea, erythrocytosis, hemorrhage, hemoconcentration,
high altitudes, intestinal obstruction (late), polycythemia vera, snorers, and
thrombotic thrombocytopenic purpura. Also conditions that increase red blood
cells (RBCs). Drugs include gentamicin, methyldopa, and pentoxifylline.
Decreased.
Andersen's disease, anemia (iron deficiency), carcinomatosis, cirrhosis, cystic
fibrosis, fat emboli, fatty liver, fluid retention, hemorrhage, hemolysis, hemolytic
reaction to chemicals or drugs or prosthetics, Hodgkin's disease, hydremia of
pregnancy, hyperthyroidism, hypervitaminosis A, hypothyroidism, idiopathic
steatorrhea, intravenous overload, leukemia, lymphoma, platelet apheresis,
pregnancy, renal cortical necrosis, sarcoidosis, severe hemorrhage, systemic lupus
erythematosus, tetralogy of Fallot, and transfusion of incompatible blood. Also,
conditions that decrease RBCs. Drugs include antibiotics, antineoplastic agents,
Apresoline (hydralazine HCl with hydrochlorothiazide), aspirin, hydantoin
derivatives, indomethacin, monoamine oxidase inhibitors, primaquine, rifampin,
sulfonamides, tridione, and zidovudine (AZT); vegetarian diet.
Description.
Hemoglobin is the oxygen-carrying pigment of the RBCs. It is composed
of amino acids that form a single protein called “globin” and a compound called
“heme.” Heme contains iron atoms and the red pigment porphyrin. Each
METABOLISM AND NUTRITION MODULE
16th Group
38
erythrocyte contains approximately 300 million molecules of hemoglobin.
(Chernecky & Berger, 2008)
2.2.12 What is anion gap?
Definition & Clinical Use
The term anion gap (AG) represents the concentration of all the
unmeasured anions in the plasma. The negatively charged proteins account for
about 10% of plasma anions and make up the majority of the unmeasured anion
represented by the anion gap under normal circumstances. The acid anions (eg
lactate, acetoacetate, sulphate) produced during a metabolic acidosis are not
measured as part of the usual laboratory biochemical profile. The H+ produced
reacts with bicarbonate anions (buffering) and the CO2 produced is excreted via
the lungs (respiratory compensation). The net effect is a decrease in the
concentration of measured anions (ie HCO3) and an increase in the concentration
of unmeasured anions (the acid anions) so the anion gap increases.
AG is calculated from the following formula:
Anion gap = [Na+] - [Cl-] - [HCO3-]
Reference range is 8 to 16 mmol/l. An alternative formula which includes
K+ is sometimes used particularly by Nephrologists. In Renal Units, K+ can vary
over a wider range and have more effect on the measured Anion Gap.
This alternative formula is:
AG = [Na+] + [K+] - [Cl-] - [HCO3-]
The reference range is slightly higher with this alternative formula. The
[K+] is low relative to the other three ions and it typically does not change much
so omitting it from the equation doesn’t have much clinical significance.
METABOLISM AND NUTRITION MODULE
16th Group
39
Major Clinical Uses of the Anion Gap
To signal the presence of a metabolic acidosis and confirm other findings
Help differentiate between causes of a metabolic acidosis: high anion gap
versus normal anion gap metabolic acidosis. In an inorganic metabolic
acidosis (eg due HCl infusion), the infused Cl- replaces HCO3 and the
anion gap remains normal. In an organic acidosis, the lost bicarbonate is
replaced by the acid anion which is not normally measured. This means
that the AG is increased.
To assist in assessing the biochemical severity of the acidosis and follow
the response to treatment
The Anion Gap can be Misleading
It is determined from a calculation involving 3 other measured ions, so the
error with an AG is much higher than that of a single electrolyte determination.
The commonest cause of a low anion gap is laboratory error in the electrolyte
determinations. The 95% error range for the AG is about +/- 5 mmol/l (ie a
10mmols/l range!)
If the AG is greater than 30 mmol/l, than it invariably means that a metabolic
acidosis is present.
If the AG is in the range 20 to 29 mmol/l, than about one third of these patients
will not have a metabolic acidosis.
Other clinical guides should also be used in deciding on the presence and
severity of a metabolic acidosis. Significant lactic acidosis may be associated with
an anion gap which remains in the reference range. Lactate levels of 5 to 10
mmols/litre are associated with a high mortality if associated with sepsis, but the
AG may be reported as within the reference range in as many as 50% of these
cases! (Dorwart & Chalmers 1975).
The anion gap is useful especially if very elevated or used to confirm other
findings. Causes of a high anion gap acidosis can be sorted out more specifically
METABOLISM AND NUTRITION MODULE
16th Group
40
by using other investigations in addition to the history and examination of the
patient. Investigations which may be very useful are:
Lactate
Creatinine
Plasma glucose
Urine ketone test
Key Fact: Hypoalbuminaemia causes a low anion gap
Albumin is the major unmeasured anion and contributes almost the whole
of the value of the anion gap. Every one gram decrease in albumin will decrease
anion gap by 2.5 to 3 mmoles. A normally high anion gap acidosis in a patient
with hypoalbuminaemia may appear as a normal anion gap acidosis. This is
particularly relevant in Intensive Care patients where lower albumin levels are
common. A lactic acidosis in a hypoalbuminaemic ICU patient will commonly be
associated with a normal anion gap.
2.2.13 What are the symptoms of anemia?
The severities of the clinical features are dependent not only on the degree
of anemia, but on the rapidity of its development. Common symptoms are general
fatigue and lassitude, breathlessness on exertion, giddiness, dimness of vision,
headache, insomnia, pallor of the skin and, much more important for diagnosis, of
mucous membranes, palpitation, functional anorexia and dyspepsia, tingling and
‘pins and needles’ in the fingers and toes (paraesthesiae). Angina pectoris (due to
myocardial hypoxia), is often present in elderly patients. Physical signs include
tachycardia, functional systolic murmurs, evidence of cardiac dilatation and, in
severe cases oedema of the ankles and crepitations at the bases of the lungs. In
addition to these general features of anemia there may be signs of nutritional
deficiency, particularly angular stomatitis, koilonychias and glossitis. Atrophy of
the papillae and mucous membrane gives the tongue a smooth glazed appearance
(chronic atrophic glossitis). The atrophy begins at the edges and later affects the
METABOLISM AND NUTRITION MODULE
16th Group
2.3 LEARNING ISSUES II
41
whole tongue. As a result the tongue appears moist and exceptionally clean.
Koilonychia is the name given to certain changes in the nails; first there is
brittleness and dryness: later there is flattening and thinning and finally concavity
(spoon-shaped nails).
2.3.1 What is the connection between Diabetes Mellitus and drowsiness?
2.3.2 How is the pathogenesys of Neuropathy?
2.3.3 What is the connection between Diabetes Mellitus and polydipsi,
polyfagia, and polyuria?
2.3.4 What is the connection between Diabetes Mellitus and body
weight?
2.3.5 What are the causes of Diabetes Mellitus Type 2?
2.3.6 What is the connection between DM Type 2 with Carbohydrate
Metabolism?
2.3.7 What is the connection between DM Type 2 with Lipid
Metabolism?
2.3.8 What is the connection between DM Type 2 with Protein
Metabolism?
2.3.9 What is the normal rate of Insulin, Haematocrit, and Creatinin?
2.3.10 What is the solution of this problem?
METABOLISM AND NUTRITION MODULE
16th Group
3.1 THE ANSWERS OF LEARNING ISSUES II
42
CHAPTER III
THIRD TUTORIAL
3.1.1 What is the connection between Diabetes Mellitus and drowsiness?
Two possible causes are often sleepy at this woman is atherosclerosis and
sleep apnea.
With time, the fatty streaks grow larger and coalesce, and the surrounding
fibrous and smooth muscle tissues proliferate to form larger and larger plaques.
Also, the macrophages release substances that cause inflammation and further
proliferation of smooth muscle and fibrous tissue on the inside surfaces of the
arterial wall. The lipid deposits plus the cellular proliferation can become so large
that the plaque bulges into the lumen of the artery and greatly reduces blood flow,
sometimes completely occluding the vessel. Even without occlusion, the
fibroblasts of the plaque eventually deposit extensive amounts of dense
connective tissue; sclerosis (fibrosis) becomes so great that the arteries become
stiff and unyielding. Still later, calcium salts often precipitate with the cholesterol
METABOLISM AND NUTRITION MODULE
16th Group
43
and other lipids of the plaques, leading to bony-hard calcifications that can make
the arteries rigid tubes. Atherosclerotic arteries lose most of their dispensability,
and because of the degenerative areas in their walls, they are easily ruptured.
Also, where the plaques protrude into the flowing blood, their rough surfaces can
cause blood clots to develop, with resultant thrombusor embolus formation,
leading to a sudden blockage of all blood flow in the artery. With the obstructive
on the artery, it can also decrease blood flow to the brain; it is this which is the
reason why women are often sleepy.
Besides atherosclerosis, other thing that easily allows the woman drowsy
is sleep apnea. Most patients develop diabetes after age 40 years, and, although
much progress has been made in therapy, the majority of diabetic patients
continue to die from macrovascular complications (i.e., cardiovascular disease).
Recently it has become clear that sleep disturbances (e.g., chronic insomnia, sleep
apnea) have an impact on health and quality of life. Neuropathy may also
contribute to the significant reduction in quality of life for patients. These
problems are frequently overlooked on routine medical interviews; furthermore, in
some cases, short-term disturbances of sleep may evolve into chronic conditions.
The indiscriminate use of sleeping pills may further disrupt the sleep-wake cycle
and contribute to stress in patients with sleep disorders. In type 2 diabetes, sleep
disturbances are believed to be common and have been attributed to impaired
glucose metabolism and general physical distress. So because this woman's
quality of sleep less, and even when sleep is enough, then it cause of this woman
is easy sleepy during the day.
3.1.2 How is the pathogenesys of Neuropathy?
The most common form of neuropathy associated with diabetes mellitus is distal
symmetric sensorimotor polyneuropathy, often accompanied by autonomic
neuropathy. This disorder is characterized by striking atrophy and loss of
myelinated and unmyelinated fibers accompanied by Wallerian degeneration,
METABOLISM AND NUTRITION MODULE
16th Group
44
segmental, and paranodal demyelination and blunted nerve fiber regeneration. All
values for nerve conduction velocity in sensory and motor nerves were slower,
and the sensory amplitude of the radial nerve and the motor amplitude of the
median nerve were lower. (Partanen et al., 1995) In both humans and laboratory
animals, this progressive nerve fiber damage and loss parallels the degree and/or
duration of hyperglycemia. Several metabolic mechanisms have been proposed to
explain the relationship between the extent and severity of hyperglycemia and the
development of diabetic neuropathy. One mechanism, activation of the polyol
pathway by glucose via AR, is a prominent metabolic feature of diabetic rat
peripheral nerve, where it promotes sorbitol and fructose accumulation, myo-
inositol depletion, and slowing of nerve conduction by alteration of neural Na(+)-
K(+)-ATPase activity or perturbation of normal physiological osmoregulatory
mechanisms. ARIs, which normalize nerve myo-inositol and nerve conduction
slowing, are currently the focus of clinical trials. Other specific metabolic
abnormalities that may play a role in the pathogenesis of diabetic neuropathy
include abnormal lipid or amino acid metabolism, superoxide radical formation,
protein glycation, or potential blunting of normal neurotrophic responses.
Metabolic dysfunction in diabetic nerve is accompanied by vascular insufficiency
and nerve hypoxia that may contribute to nerve fiber loss and damage. (Greene, et
al, 1992)
3.1.3 What is the connection between Diabetes Mellitus and polydipsi,
polyuria, and polyfagia??
Excessive thirst (polydipsia): A person with diabetes develops high blood
sugar levels, which overwhelms the kidney's ability to reabsorb the sugar as the
blood is filtered to make urine. Excessive urine is made as the kidney spills the
excess sugar. The body tries to counteract this by sending a signal to the brain to
dilute the blood, which translates into thirst. The body encourages more water
METABOLISM AND NUTRITION MODULE
16th Group
45
consumption to dilute the high blood sugar back to normal levels and to
compensate for the water lost by excessive urination.
Excessive urination (polyuria): Another way the body tries to get rid of the
extra sugar in the blood is to excrete it in the urine. This can also lead to
dehydration because excreting the sugar carries a large amount of water out of the
body along with it.
Excessive eating (polyphagia): If the body is able, it will secrete more
insulin in order to try to deal with the excessive blood sugar levels. Moreover, the
body is resistant to the action of insulin in type 2 diabetes. One of the functions of
insulin is to stimulate hunger. Therefore, higher insulin levels lead to increased
hunger and eating. Despite increased caloric intake, the person may gain very
little weight and may even lose weight.
3.1.4 What is the connection between Diabetes Mellitus and body
weight?
Obesity can increase risk factor to type 2 diabetes mellitus.In type 2 DM, insulin resistance is often associated with abdominal obesity
(as opposed to hip and thigh obesity) and hypertriglyceridemia (Kasper, 2005).
Type 2 DM is characterized by three pathophysiologic abnormalities:
impaired insulin secretion, peripheral insulin resistance, and excessive hepatic
glucose production. Obesity, particularly visceral or central (as evidenced by the
hip-waist ratio), is very common in type 2 DM. Adipocytes secrete a number of
biologic products (leptin, TNF-α, free fatty acids, resistin, and adiponectin) that
modulate insulin secretion, insulin action, and body weight and may contribute to
the
insulin
METABOLISM AND NUTRITION MODULE
16th Group
46
resistance. In the early stages of the disorder, glucose tolerance remains normal,
despite insulin resistance, because the pancreatic β cells compensate by increasing
insulin output. As insulin resistance and compensatory hyperinsulinemia progress,
the pancreatic islets in certain individuals are unable to sustain the
hyperinsulinemic state. IGT, characterized by elevations in postprandial glucose,
then develops. A further decline in insulin secretion and an increase in hepatic
glucose production lead to overt diabetes with fasting hyperglycemia. Ultimately,
β cell failure may ensue. Markers of inflammation such as IL-6 and C-reactive
protein are often elevated in type 2 diabetes (Kasper, 2005).
The decreased ability of insulin to act effectively on peripheral target
tissues (especially muscle and liver) is a prominent feature of type 2 DM and
results from a combination of genetic susceptibility and obesity (Kasper, 2005).
Another emerging theory proposes that elevated levels of free fatty acids, a
common feature of obesity, may contribute to the pathogenesis of type 2 DM.
Free fatty acids can impair glucose utilization in skeletal muscle, promote glucose
production by the liver, and impair β cell function (Kasper, 2005).
Diabetes mellitus can reduce body weight.
Body weight is dynamic due to fat accumulation (triacylglicerol) in
adipocytes cells. Fat is dynamic because the amount of fat follow the energy
situation in one's body. If someone is having excess energy, the food material will
be deflected into the path of formation triacylglicerol. However, if someone
experienced hunger, triacylglicerol stored will be split into 3 fatty acids and 1
glycerol. Fatty acids will be distributed and to enter into the lane on the
mitochondrial oxidation β cells that would produce, acetyl CoA. Acetyl-CoA will
enter the Krebs cycle which produces nucleoside phosphate compounds-energy
high (Murray, 2003).
METABOLISM AND NUTRITION MODULE
16th Group
47
In solving triacylglycerol (lipolysis) is required enzyme hormone-sensitive
lipase enzyme which is sensitive to insulin levels. The enzyme is inhibited by
insulin. However, if insulin levels are decreased (as in diabetes), the inhibition of
lipolysis is greatly reduced. Thus, the rate of formation of fatty acids will increase.
Fatty acid that increases will shift the use of glucose as energy to the use of fatty
acids for energy. Swift fatty acids will result in the number of acetyl-CoA
resulting in β oxidation. Acetyl-CoA which many will be deflected towards the
formation of ketone compounds which, if too many will lead to many
complications associated blood acidosis (Murray, 2003).
Thus, low levels of insulin will lead to lower the barriers for hormone-
sensitive lipase, so that the process of lipolysis will go well. The number of
reserves will result in triacylglycerol lipolysis in adipocytes cells is reduced, so
that the weight will decrease.
METABOLISM AND NUTRITION MODULE
16th Group
48
3.1.5 What are the causes of Diabetes Mellitus Type 2?
Diabetes Mellitus (DM) is one health problem impact on productivity and
can lower the Human Resources. This disease affects not only individually, but
the health system a country. Although no national survey, in line with changes
lifestyle, including eating patterns of Indonesian society is estimated patient. DM
is increasing, especially in adults and older age groups in all socio-economic
status. Currently, efforts to control disease DM has not occupied the main
priorities in health care, although the known negative impact thereof large enough
between, other chronic complications in chronic heart disease, hypertension,
brain, system nerve, liver, eyes and kidneys. DM is a degenerative disease, where
an interruption occurs metabolism of carbohydrates, fats and proteins and is
characterized by high blood sugar levels (hyperglycemia) and in urine.
Clinically, this disease is progressive travel and tend to involve too fat or
protein metabolism disorders. Increased blood glucose levels because of
utilization that are not going perfectly in turn often led to the clinical
abnormalities of blood lipid levels. To obtain a normal glucose levels in the blood
necessary drugs that can stimulate beta cells to increase insulin secretion (insulin
secretagogue) or when required by the substitution of insulin, in addition to
efficacious drugs that reduce insulin resistance (insulin sensitizers).
Inadequate phase 1, which is then followed by performance improvement
phase 2 insulin secretion, in the early stages will not cause disruption to the blood
glucose levels. Clinically, then at the stage of decompensation, can be detected
condition called impaired glucose tolerance which is also called as a prediabetic
state. At this stage of compensatory mechanisms have started no longer adequate,
the body that may be deficient in relative terms, an increase in postprandial blood
glucose levels. In impaired glucose tolerance (IGT) was found postprandial blood
glucose levels, or after being fed a solution of 75 g glucose load with Oral
Glucose Tolerance Test (oral glucose tolerance), ranged between 140-200 mg /
dl. Also known as prediabetes, when fasting blood glucose levels between 100-
METABOLISM AND NUTRITION MODULE
16th Group
49
126 mg / dl, which is also known as Fasting Blood Glucose Disturbed (GDPT).
State of hyperglycemia that occurs, both at the stage of chronic diabetes,
or acute postprandial hyperglycemia that occurred were ulangkali every day since
the stage of IGT, has negative long-term tissue complications of chronic
diabetes.Tingginya blood glucose levels (glucotoxicity) which followed by
dyslipidemia (lipotoxicity) is responsible for tissue damage both directly through
oxidative stress, and widespread process of glycosylation.
Insulin resistance from prominent role since the change or conversion into
DMT2 TGT phase. It is said that at the start of dominant factor of insulin
resistance as a cause of hyperglycemia as well as a variety of tissue damage. This
is evident from the fact that in the early stages DMT2, although the serum insulin
levels are high enough, but hyperglycemia can still occur. Tissue damage occurs,
particularly microvascular, increased dramatically at this stage of diabetes,
whereas macrovascular disorders have emerged since prediabetes. Increasing
levels of insulin resistance can be seen also from increased levels of fasting and
postprandial blood glucose. Accordingly, at the higher levels of hepatic insulin
resistance, the lower the ability of inhibition to the process of glycogenolysis and
gluconeogenesis, causing the higher the level of hepatic glucose production.
We have to know that, Secreation of phase (Acute insulin secretion
responce = AIR) is the secretion of insulin that occurs immediately after
stimulation of beta cells, arise quickly and ended too quickly. Secretion of phase 1
(AIR) usually have a relatively high peak, because it is necessary to anticipate the
blood glucose levels typically rise sharply, immediately after eating. Performance
of a rapid and adequate water is essential for normal glucose regulation because
pasa turn contribute significantly in controlling postprandial blood glucose
levels. Thus, the presence of normal water needed to sustain the process of
physiological glucose metabolism. WATER normal lasting, beneficial in
preventing the occurrence of acute hyperglycemia after a meal or postprandial
METABOLISM AND NUTRITION MODULE
16th Group
50
blood glucose spikes (postprandial spike) with all consequences thereof including
compensed inemia.
Furthermore, after the secretion phase 1 ended, appear secretion phase 2
(sustained phase, latent phase), where insulin secretion increased again slowly and
survive in a relatively longer time. After the end of phase 1, the task of blood
glucose regulation subsequently taken over by the secretion phase 2. Insulin
secretion phase 2, which lasted relatively long, how high the peak (quantitative)
will be determined by how much the blood glucose level at the end of phase 1, in
addition to insulin resistance factor. So, a kind of adjustment mechanism of
secretion of phase 2 to phase 1 previous performance. If the phase 1 secretion is
inadequate, there was a mechanism of compensation in the form of increased
secretion of insulin in Phase 2.Increased insulin production is essentially aimed at
meeting the needs of the body for blood glucose levels (postprandial) remained
within normal limits. In the prospective course of the disease, insulin secretion
phase 2 will be heavily influenced by phase 1.In the figure below (Fig. 2)
demonstrated the dynamics of insulin secretion in normal circumstances,
Disturbed Glucose Tolerance (IGT = Impaired Glucose Tolerance), and Type 2
Diabetes Mellitus.
Usually, with a normal phase 1 performance, accompanied also by the
action of insulin which is also normal in the network (without insulin resistance),
the secretion of phase 2 will also be normal. Thus no additional need (extra)
synthesis and secretion of insulin in Phase 2 above normal in order to maintain the
state of normoglycaemia.This is a physiological condition which is ideal for
without raising blood glucose levels that may impact glucotoxicity, also without
hyperinsulinemia with various negative impacts.
METABOLISM AND NUTRITION MODULE
16th Group
51
So, it can be concluded trip DMT2 disease, initially determined by the
performance of Phase 1 which then gives a negative impact on the performance of
phase 2, and a direct result of elevated levels of blood glucose
(hyperglycemia). Hyperglycemia occurs not only due to impaired insulin secretion
(insulin deficiency), but at the same time also by the low response of body tissues
to insulin (insulin resistance).Disruption or environmental influences such as
lifestyle or obesity will accelerate progression of the disease. Impaired glucose
metabolism will continue in fat and protein metabolism disorders and the damage
to various body tissues. The series of disorders that are motivated by insulin
resistance, other than intolerance to glucose and its various consequences, often
leading to a collection of symptoms called metabolic syndrome.
METABOLISM AND NUTRITION MODULE
16th Group
Insu
lin
Sec
reti
on
Intravenous glucose stimulation
First-Phase
SecondPhase
IGT
Normal
Type 2DM
Basal
52
3.1.6 What is the connection between Diabetes Mellitus Type 2 and
Carbohydrate Metabolism?
With type 2 diabetes, the impairment of glucose metabolism arises as a
result of a decreased sensitivity to insulin by the body’s cells. This means that the
cells do not respond to insulin to take up glucose from the bloodstream and utilize
it. This is known as insulin resistance. This causes glucose in human blood cannot
be converted into glycogen by hepar’s cells (glycogenesys doesn’t work). And
also other kind of cells do not use blood glucose due to its insensitivity caused by
the malfunction of beta cells of islets of Langerhans.
Compensatory mechanism:
The insulin levels in the blood are elevated, above the norm
(hyperinsulinemia) as the pancreas secretes higher amounts of glucose in an
attempt to overcome this resistance (compensatory mechanism). This
mechanism causes hyperinsulinemia until bile is overworked and
malfunctioned as well, leading to inappropriate amount of insulin in human
body.
Overlap point with lipogenesys:
Upon consuming foods, particularly carbohydrates, the digestive system along
with the liver, break down the food into simple sugars like glucose. Glucose
then enters the blood stream where it is transported to cells throughout the
body. Excess glucose is converted to glycogen and stored in the liver and
muscles. Any remaining glucose may be converted for fat storage. This blood
glucose regulating mechanism is primarily controlled by the hormone, insulin,
which is secreted by the pancreas (beta cells in the islets of Langerhan’s).
Insulin triggers cells to take up glucose from the blood so that individual
cells can burn this glucose for energy. Alternatively, excess glucose is converted
into glycogen and stored in the liver due to the action of insulin. In insulin
resistance, seen in impaired glucose tolerance (or pre-diabetes), the body’s cells
and liver do not respond to insulin. Excess glucose builds up in the blood stream
METABOLISM AND NUTRITION MODULE
16th Group
53
and the pancreas attempts to secrete more insulin. This excess insulin secretion
may not always trigger the desired effect resulting higher than normal blood
glucose levels. Over time, insulin resistance and pre-diabetes will lead to type 2
diabetes, also known as adult-onset diabetes or non-insulin dependent diabetes.
3.1.7 What is the connection between Diabetes Mellitys Type 2 with
lipid metabolism?
After a normal meal there is an ample supply of carbohydrate, and the fuel
for most tissues is glucose. In the starving state, glucose must be spared for use by
the central nervous system (which is largely dependent on glucose) and the
erythrocytes (which are wholly reliant on glucose). Other tissues can utilize
alternative fuels such as fatty acids and ketone bodies. As glycogen reserves
become depleted, so amino acids arising from protein turnover and glycerol
arising from lipolysis are used for gluconeogenesis. These events are largely
controlled by the hormones insulin and glucagon. In diabetes mellitus there is
either impaired synthesis and secretion of insulin (type 1 diabetes mellitus) or
impaired sensitivity of tissues to insulin action (type 2 diabetes mellitus), leading
to severe metabolic derangement.
The nutritional state of the organism is the main factor regulating the rate
of lipogenesis. Thus, the rate is high in the well-fed animal whose diet contains a
high proportion of carbohydrate. It is depressed under conditions of restricted
caloric intake, on a fat diet, or when there is a deficiency of insulin, as in diabetes
mellitus. These latter conditions are associated with increased concentrations of
plasma free fatty acids, and an inverse relationship has been demonstrated
between hepatic lipogenesis and the concentration of serum-free fatty acids.
Insulin stimulates lipogenesis by several other mechanisms as well as by
increasing acetyl-CoA carboxylase activity. It increases the transport of glucose
into the cell (eg, in adipose tissue), increasing the availability of both pyruvate for
fatty acid synthesis and glycerol 3-phosphate for esterification of the newly
formed fatty acids, and also converts the inactive form of pyruvate dehydrogenase
METABOLISM AND NUTRITION MODULE
16th Group
54
to the active form in adipose tissue but not in liver. Insulin also—by its ability to
depress the level of intracellular cAMP—inhibits lipolysis in adipose tissue and
thereby reduces the concentration of plasma free fatty acids and therefore long-
chain acyl- CoA, an inhibitor of lipogenesis.
Free fatty acids from the circulation are the main source during starvation,
the feeding of high-fat diets, or in diabetes mellitus, when hepatic lipogenesis is
inhibited. In adipose tissue, insulin stimulates glucose uptake, its conversion to
fatty acids, and their esterification; and inhibits intracellular lipolysis and the
release of free fatty acids. Insulin inhibits the release of free fatty acids from
adipose tissue, which is followed by a fall in circulating plasma free fatty acids. It
enhances lipogenesis and the synthesis of acylglycerol and increases the oxidation
of glucose to CO2 via the pentose phosphate pathway.
In poorly controlled type 1 diabetes mellitus, patients may become
hyperglycemic, partly as a result of lack of insulin to stimulate uptake and
utilization of glucose and partly because of increased gluconeogenesis from amino
acids in the liver. At the same time, the lack of insulin results in increased
lipolysis in adipose tissue, and the resultant free fatty acids are substrates for
ketogenesis in the liver.
Increased fatty acid oxidation is a characteristic of starvation and of
diabetes mellitus, leading to ketone body production by the liver (ketosis). Ketone
bodies are acidic and when produced in excess over long periods, as in diabetes,
cause ketoacidosis, which is ultimately fatal. Ketosis is mild in starvation but
severe in diabetes mellitus and ruminant ketosis.
Lipid is mobilized from adipose tissue as free fatty acids (FFA) attached to
serum albumin. Abnormalities of lipoprotein metabolism cause various hypo- or
hyperlipoproteinemias. The most common of these is diabetes mellitus, where
insulin deficiency causes excessive mobilization of FFA and underutilization of
chylomicrons and VLDL, leading to hypertriacylglycerolemia. Most other
pathologic conditions affecting lipid transport are due primarily to inherited
defects, some of which cause hypercholesterolemia, and premature
atherosclerosis. (Murray, 2003)
METABOLISM AND NUTRITION MODULE
16th Group
55
3.1.8 What is the connection between Diabetes Mellitus Type 2 with
protein metabolism?
During the few hours after a meal when excess quantities of nutrients are
available in the circulating blood, not only carbohydrates and fats but proteins as
well are stored in the tissues; insulin is required for this to occur. The manner in
which insulin causes protein storage is not as well understood as the mechanisms
for both glucose and fat storage. Some of the facts follow.
1. Insulin stimulates transport of many of the amino acids into the cells .
Among the amino acids most strongly transported are valine, leucine,
isoleucine, tyrosine, and phenylalanine. Thus, insulin shares with
growth hormone the capability of increasing the uptake of amino acids
into cells. However, the amino acids affected are not necessarily the
same ones.
2. Insulin increases the translation of messenger RNA, thus forming new
proteins. In some unexplained way, insulin “turns on” the ribosomal
machinery. In the absence of insulin, the ribosomes simply stop
working, almost as if insulin operates an “on-off” mechanism.
3. Over a longer period of time, insulin also increases the rate of
transcription of selected DNA genetic sequences in the cell nuclei, thus
forming increased quantities of RNA and still more protein synthesis—
especially promoting a vast array of enzymes for storage of
carbohydrates, fats, and proteins.
4. Insulin inhibits the catabolism of proteins, thus decreasing the rate of
amino acid release from the cells, especially from the muscle cells.
Presumably this results from the ability of insulin to diminish he normal
degradation of proteins by the cellular lysosomes.
5. In the liver, insulin depresses the rate of gluconeogenesis. It does this
by decreasing the activity of the enzymes that promote
METABOLISM AND NUTRITION MODULE
16th Group
56
gluconeogenesis. Because the substrates most used for synthesis of
glucose by gluconeogenesis are the plasma amino acids, this
suppression of gluconeogenesis conserves the amino acids in the
protein stores of the body.
In summary, insulin promotes protein formation and prevents the
degradation of proteins.
Insulin Lack Causes Protein Depletion and Increased Plasma Amino Acids.
Virtually all protein storage comes to a halt when insulin is not available.
The catabolism of proteins increases, protein synthesis stops, and large quantities
of amino acids are dumped into the plasma. The plasma amino acid concentration
rises considerably, and most of the excess amino acids are used either directly for
energy or as substrates for gluconeogenesis. This degradation of the amino acids
also leads to enhanced urea excretion in the urine. The resulting protein wasting is
one of the most serious of all the effects of severe diabetes mellitus. It can lead to
extreme weakness as well as many deranged functions of the organs. (Guyton and
Hall, 2006)
3.1.9 What is the normal rate of Insulin, Haematocrit, and Creatinin?
Insulin and Insulin Antibodies—Blood Norm.
Free insulin: fasting ≤25 IU/mL (<172.5 pmol/L, SI units). (Norms and
standardization of the test method vary widely by laboratory.)
Insulin Level via Radioimmunoassay:
SI Units
Adult, fasting level <17 μIU/mL or 1.00 mg/L <117 pmol/L
Newborn 3–20 μIU/mL 21–139 pmol/L
Infant <13 μIU/mL ≤89 pmol/L
Prepubertal child <13 μIU/mL ≤89 pmol/L
METABOLISM AND NUTRITION MODULE
16th Group
57
SI Units
Panic levels >30 μIU/mL >207 pmol/L
Last trimester, amniotic fluid 11.3 μIU/mL 78 pmol/L
Insulin Antibodies.
Undetectable to less than 4% when using either bovine or porcine insulin as a
reagent. Insulin antibodies have been shown to occur more frequently with aging
and more in females than in males.
Increased Insulin.
Acromegaly, Beckwith-Wiedemann syndrome, beta-cell adenoma, Cushing's
syndrome, dystrophia myotonica, familial fructose and galactose intolerance,
hyperinsulinism, hypoglycemia, insulin-resistance syndromes, insulinoma, liver
disease, non–insulin-dependent diabetes mellitus, metabolic syndrome,
nesidioblastosis, obesity, overdose of insulin, pancreatic islet cell lesion, and
pheochromocytoma. Drugs include albuterol, calcium gluconate in the newborn,
estrogen, fructose, glucagon, glucose, insulin, levodopa, medroxyprogesterone,
oral contraceptives, prednisolone, quinine, quinidine, spironolactone, sucrose,
terbutaline, tolazamide, and tolbutamide.
Decreased Insulin.
Diabetes mellitus, hyperglycemia, hypopituitarism, and pancreatectomy-induced
diabetes. Drugs include beta-adrenergic blockers, asparaginase, calcitonin,
cimetidine, diazoxide, ethacrynic acid, ethyl alcohol (ethanol), ether, furosemide,
metformin, nifedipine, phenformin, phenobarbital, phenytoin, and thiazide
diuretics.
Positive Insulin Antibodies.
Factitious hypoglycemia, autoimmune insulin syndrome (AIS).
METABOLISM AND NUTRITION MODULE
16th Group
58
Negative Insulin Antibodies.
Normal finding. Also negative in insulinoma.
Description.
Insulin is a hormone that regulates carbohydrate metabolism. It is produced in the
pancreas by the beta cells of the islets of Langerhans, and its rate of secretion is
determined primarily by the level of blood glucose. The radioimmunoassay test
measures endogenous insulin by using a series of tubes containing a fixed amount
of antibody label and an aliquot of standard, control, or unknown. The client's
unlabeled antigen in the blood competes with labeled antigen for antibody-binding
sites. The percentage of antigen bound to antibody is related to the total antigen
present and is reflected by the distribution of a radioactive label. Low
immunoreactive insulin levels have been associated with a higher risk of
developing degenerative diseases such as atherosclerosis, hypertension, and
dyslipidemia. Insulin antibodies, also referred to as anti–insulin-Ab, may be
present in diabetic clients treated for several weeks or more with conventional
insulin. These antibodies may also be present in persons who have never received
insulin but have autoimmune insulin syndrome (AIS), a rare condition
characterized by hyperinsulinemia and hypoglycemia. For diabetic clients, this
test may be used with C-peptide to determine whether hypoglycemia is caused by
insulin abuse. Insulin antibodies are transferred through the placenta and are
present in 30%–50% of children at the time of diagnosis before beginning insulin
therapy.
Hematocrit (Hct)—Blood Norm.
SI Units
Females
Adult 37%–47% 0.37–0.47
Pregnant 30%–46% 0.30–0.46
Adult Males 40%–54% 0.40–0.54
METABOLISM AND NUTRITION MODULE
16th Group
59
SI Units
Children
Neonates 40%–68% 0.40–0.68
3 months 29%–54% 0.29–0.54
1–2 years 35%–44% 0.35–0.44
6–10 years 31%–45% 0.31–0.45
Panic Levels <15% or >60% <0.15 or >0.60
Panic Level Symptoms and Treatment—Increased
NOTE: Treatment choice(s) depend(s) on client's history and condition and episode history.
Cause Symptoms Possible Treatments
Hemoconcentration Decreased pulse pressure and volume, decreased skin turgor, decreased venous filling, dry mucous membranes, low central venous pressure, orthostatic hypotension, tachycardia, thirst and weakness
Administer IV fluids.monitor hematocrit.Stop or reduce dose of diuretics if they are contributors to condition.
True polycythemia overtransfusion
Extremity pain and redness, facial flushing, irritability, anasarca decreasing QRS voltage with severe fluid overload
Administer IV fluids.Monitor hematocrit.Observe for signs of thrombosis.Perform bloodletting by venipuncture (phlebotomy).
Panic Level Symptoms and Treatment—Decreased
Cause Symptoms Possible Treatments
Hemodilution Rales, anxiety, edema, hypertension, jugular venous distention, restlessness, and shortness of breath
Administer diuretics.Restrict sodium.Restrict fluids.Monitor hematocrit and intake and output.Administer oxygen.
Blood loss Hypotension, bleeding, hypoxia Identify and treat cause of
METABOLISM AND NUTRITION MODULE
16th Group
60
Cause Symptoms Possible Treatments
bleeding.Give isotonic fluids.Perform blood transfusion.Administer omeprazole (if blood loss is caused by bleeding esophageal varices).Protect airways; administer oxygen as needed.
Increased.
Addison's disease, blood doping (autologous transfusion to improve athletic
performance), burns (severe), dehydration (severe), diabetes mellitus, diarrhea,
eclampsia, erythrocytosis, hemorrhage, hemoconcentration, pancreatitis (acute),
polycythemia, shock, and tetralogy of Fallot. Any condition that increases red
blood cells (RBCs).
Decreased.
Anemia, bone marrow hyperplasia, burns (severe), cardiac decompensation,
cirrhosis, congestive heart failure, cystic fibrosis, fatty liver, fluid overload,
hemolytic reactions to chemicals or drugs or prosthetics, hemorrhage, hydremia of
pregnancy, hyperthyroidism, hypothyroidism, idiopathic steatorrhea, intestinal
obstruction (late), leukemia, overhydration, pancreatitis (hemorrhagic),
pneumonia, and pregnancy. Also, conditions that decrease RBCs. Drugs include
acetaminophen, acetohexamide, aminosalicylic acid, amphotericin, antimony
potassium tartrate, antineoplastic agents, antibiotics, atabrine hydrochloride,
chloramphenicol, chloroquine hydrochloride or phosphate, doxapram
hydrochloride, ethosuximide, ethotoin, furazolidone, haloperidol, hydralazine
hydrochloride, indomethacin, isocarboxazid, isoniazid, mefenamic acid,
mephenytoin, mercurial diuretics, metaxalone, methaqualone, methsuximide,
methyldopa, methyldopate hydrochloride, nitrates, nitrofurantoin, novobiocin
sodium, oleandomycin, oxyphenbutazone, paramethadione, pargyline
hydrochloride, penicillins, phenacemide, phenelzine sulfate, phenobarbital,
METABOLISM AND NUTRITION MODULE
16th Group
61
phensuximide, phenylbutazone, phenytoin sodium, phytonadione, primidone,
radioactive agents, rifampin, spectinomycin hydrochloride, sulfonamides,
tetracyclines, thiazide diuretics, thiocyanates, thiosemicarbazones, tolazamide,
tolbutamide, tranylcypromine sulfate, trimethadione, tripelennamine
hydrochloride, troleandomycin, valproic acid, vegetarian diet, vitamin A, and
zidovudine (AZT).
Description.
Hematocrit is the percentage of red blood cells in a volume of whole blood.
Creatinine—Serum Norm.
SI Units
Jaffe, Manual Method 0.6–1.6 mg/dL 52–142 μmol/day
Jaffe, Kinetic or Enzymatic Method
Adults
Females 0.5–1.1 mg/dL 44–97 μmol/L
Males 0.6–1.2 mg/dL 53–105 μmol/L
Elderly May be lower May be lower
Children
Cord blood 0.6–1.2 mg/dL 53–105 μmol/L
Newborn 0.8–1.4 mg/dL 71–124 μmol/L
Infant 0.7–1.7 mg/dL 62–150 μmol/L
1 year, female ≤0.5 mg/dL ≤44 μmol/L
1 year, male ≤0.6 mg/dL ≤53 μmol/L
2–3 years, female ≤0.6 mg/dL ≤53 μmol/L
2–3 years, male ≤0.7 mg/dL ≤62 μmol/L
4–7 years, female ≤0.7 mg/dL ≤62 μmol/L
4–7 years, male ≤0.8 mg/dL ≤71 μmol/L
8–10 years, female ≤0.8 mg/dL ≤71 μmol/L
METABOLISM AND NUTRITION MODULE
16th Group
62
SI Units
8–10 years, male ≤0.9 mg/dL ≤80 μmol/L
11–12 years, female ≤0.9 mg/dL ≤80 μmol/L
11–12 years, male ≤1.0 mg/dL ≤88 μmol/L
13–17 years, female ≤1.1 mg/dL ≤97 μmol/L
13–17 years, male ≤1.2 mg/dL ≤106 μmol/L
18–20 years, female ≤1.2 mg/dL ≤106 μmol/L
18–20 years, male ≤1.3 mg/dL ≤115 μmol/L
Increased.
Values are 20–40% higher in the late afternoon than in the morning. Acromegaly,
allergic purpura, amyloidosis, analgesic abuse, azotemia (prerenal, postrenal),
congenital hypoplastic kidneys, congestive heart failure, diabetes mellitus, diet
(high meat content), gigantism, glomerulonephritis (chronic), Goodpasture's
syndrome, gout, hemoglobinuria, high dietary intake, hypovolemic shock,
hypothyroidism, infants (first 2 weeks of life), intestinal obstruction, Kimmelstiel-
Wilson syndrome, micro albuminemia, metal poisoning, multiple myeloma,
muscle destruction, nephritis, nephropathy (hypercalcemic, hypokalemic),
nephrosclerosis, pancreatitis (necrotizing), polyarteritis nodosa, polycystic
disease, preeclampsia, pyelonephritis, renal artery stenosis or thrombosis, renal
cortical necrosis, renal failure, renal vein thrombosis, renal tuberculosis,
rheumatoid arthritis (active), scleroderma, sickle cell anemia, subacute bacterial
endocarditis, systemic lupus erythematosus, testosterone therapy, toxic shock
syndrome, uremia, urinary obstruction, and vomiting. Drugs include
acetohexamide, acyclovir, ammonia (inhaled), amphotericin B, androgens,
arginine, bleomycin-induced pulmonary toxicity, Bromsulphalein, captopril,
cephalosporins (Cefoxitin, cephalexin), cimetidine, cinchophen, clofibrate,
corticosteroids, diacetic acid, diuretics, disopyramide phosphate, dopamine,
fenofibrate, fosinopril, fructose, gentamicin sulfate, glucose, hydralazine
hydrochloride, hydroxyurea, Lipomul, lithium carbonate, losartan, mannitol,
METABOLISM AND NUTRITION MODULE
16th Group
63
meclofenamate sodium, methicillin sodium, metoprolol tartrate, minoxidil,
mithramycin, nitrofurantoin, nitrogen oxide (inhaled), propranolol, protein,
pyruvate, sulfobromophthalein, sulfonamides, streptokinase, testosterone,
testosterone cypionate, testosterone enanthate, testosterone propionate,
triamterene, and viomycin. Herbal or natural remedies include products
containing aristolochic acids (Akebia spp., Aristolochia spp., Asarum spp.,
birthwort, Bragantia spp., Clematis spp., Cocculus spp., Diploclisia spp.,
Dutchman's pipe, Fang chi, Fang ji, Guang Kan-Mokutsu, Menispernum spp.,
Mokutsu, Mu tong, Sinomenium spp., and Stephania spp.).
Decreased.
Diabetic ketoacidosis (artifactual decrease) and muscular dystrophy. Drugs
include cefoxitin sodium, cimetidine, chlorpromazine, chlorprothixene, marijuana,
thiazide diuretics, and vancomycin. Herbal or natural remedies include Cordyceps
sinensis.
Description.
Creatinine is produced continuously as a nonprotein end product of anaerobic
energy-producing creatine phosphate metabolism in skeletal muscle. Because it is
continually and easily excreted by the renal system, increased levels indicate a
slowing of the glomerular filtration rate. Creatinine is thus a very specific
indicator of renal function, revealing the balance between creatinine formation
and excretion. A diurnal variation in creatinine may be related to meals, with
troughs occurring around 0700 (7 AM) and peaks occurring around 1900 (7 PM).
Lipid Profile—Blood Norm.
See individual test listings for age-specific norms, including norms for children.
SI Units
Lipids, total 400–800 mg/dL 4.0–8.0 g/L
METABOLISM AND NUTRITION MODULE
16th Group
64
SI Units
Triglycerides 10–190 mg/dL 0.2–4.8 mmol/L
HDL cholesterol
Females 35–85 mg/dL 0.9–2.2 mmol/L
Males 30–65 mg/dL 0.8–1.7 mmol/L
LDL cholesterol 80–190 mg/dL 2.0–4.9 mmol/L
VLDL cholesterol (calculated) ≤30 mg/dL <0.78 mmol/L
Total-to-HDL cholesterol ratio Median = 5
Condition Triglycerides Total Cholesterol HDL LDL
Alcoholism Increase Increase Increase Increase
Aortic aneurysm Increase Increase Increase Increase
Aortitis Increase Increase Increase Increase
Arteriosclerosis Increase Increase Decrease Increase
Diabetes mellitus Increase Increase Increase Increase
Glycogen storage Increase — — Increase
Hyperalimentation Decrease Decrease Decrease Decrease
Hypercholesterolemia Increase Increase — Increase
Hyperlipoproteinemia Increase Increase Increase Increase
Hypothyroid Increase — Decrease —
Malabsorption Decrease Decrease Decrease Decrease
Myxedema Increase Increase Increase Increase
Nephrotic syndrome Increase Increase Increase Increase
Pancreatitis Increase Increase Increase Increase
Description.
Lipid profile is a battery of laboratory studies to help determine the risk factors in
coronary artery disease. Blood lipids comprise cholesterol, triglycerides, and
phospholipids. Fasting lipid profiles are recommended every 5 years in clients
METABOLISM AND NUTRITION MODULE
16th Group
65
older than age 19. See individual test sections for further descriptions of the
components of the lipid profile, as well as levels for which lifestyle changes and
therapeutic drug regimens are recommended. (Chernecky & Berger, 2008)
Total Cholesterol—Coronary Heart Disease Risk
Desirable Borderline High Risk High Risk
Norm mg/dL
SI Units mmol/L
mg/dL SI Units mmol/L
mg/dL SI Units mmol/L
Adult <200 <5.18 200–239
5.18–6.19 ≥240 ≥6.22
Child <170 <4.40 170–199
4.40–5.15 ≥200 ≥25.18
HDL Cholesterol—Coronary Heart Disease Risk
Very Low Risk Low Risk Moderate Risk High Risk
mg/dL SI Units mmol/L
mg/dL SI Units mmol/L
mg/dL SI Units mmol/L
mg/dL SI Units mmol/L
Adults >60 >1.554 45–59 1.16–1.53
35–45 0.91–1.16
<35 <0.91
Total to HDL Ratio
Coronary Heart Disease Risk
Average Risk 2 × Average Risk
3 × Average Risk
Male 5.0 9.6 23.4
Female 4.4 7.1 11.0
LDL Cholesterol—Coronary Heart Disease Risk
Low Risk Moderate Risk High Risk
Optima Near Optimal Borderline High High Very High
mg/dL SI Units mg/dL SI Units mg/dL SI Units mg/dL SI Units mg/dL SI Units
<100 <2.59 100– 2.59– 130– 3.37– 160– 4.14– >190 >4.92
METABOLISM AND NUTRITION MODULE
16th Group
66
129 3.34 159 4.12 189 4.89
3.1.10 What is the solution of this problem?
The aim of treatment of diabetes mellitus is consistently normalize blood
glucose levels with minimum variation. Recent studies suggest that maintaining
blood glucose levels as normal and as often as possible to reduce morbidity and
mortality. This objective is achieved through a variety of ways, each of which is
adjusted individually.
Insulin: Type 1 diabetes requires insulin therapy. There are various types
of insulin with the origin and purity of different. Insulin also vary in
aspects of work, the peak time of work, and length of work. Although the
injection of subcutaneous insulin is usually given 3-4 times a day after the
basal blood glucose levels measured, but treatment for people with type 1
diabetes in the future will most likely be directed toward a more frequent
injections. Available subcutaneous insulin pump that can be programmed
for release a certain amount of insulin within a certain time interval per
day. If the planned changes to the regular schedule, then the pump can be
programmed to increase or reduce the amount of insulin secreted. Insulin
pump has the advantage that is not needed injection, an important
consideration for all people with diabetes, especially children. Lack of
programming failure pump is likely causing hypoglycemia or
hyperglycemia, as well as damage to the pump which caused the death. In
addition, there is danger of infection given the interruption of blood flow
METABOLISM AND NUTRITION MODULE
16th Group
67
and decreased immune system that occurs in most patients with diabetes.
The pump is also very expensive.
People with type 2 diabetes, although considered not insulin dependent,
can also benefit from insulin therapy. In people with type 2 diabetes, may
occur insulin deficiency or insulin release produced less effective because
a slight change. People with type 2 diabetes can be treated with oral
hypoglycemic drugs. These medications can be used effectively only if the
individual shows insulin secretion. These drugs appear to work by
stimulating pancreatic beta cells to increase insulin release and increased
sensitivity to insulin receptor cells. These drugs also appear to reduce
gluconeogenesis by the liver. Oral hypoglycemic medications vary in
aspects of work, time fatherly reached peak employment, and length of
work. Drugs are contraindicated for individuals with kidney disease.
Education and adherence to the diet: Another important component in the
treatment of diabetes type 1 and 2. Diabetes diet plan is calculated on an
individual basis depending on the needs of growing, weight loss plan
(typically for patients with type 2 diabetes), and activity level.
Distribution is usually 50-60% of calories from complex carbohydrates,
20% from protein, and 30% from fat. Diet also includes fiber, vitamins,
and mineral. Most patients with type 2 diabetes recovering near-normal
blood glucose levels with dietary intervention only because of the role of
obesity factor.
Sports programs, especially for people with type 2 diabetes. It is the third
therapeutic interventions for diabetes mellitus. Exercise, combined with
the liberation of the diet, will promote weight loss can improve insulin
sensitivity distinction. For both types of diabetes, exercise is proven to
increase the use of glucose by the cells so that blood glucose levels down.
Exercise also can increase the sensitivity of cells to insulin.
People with type 1 diabetes must be careful when exercising, due to a
decline in blood glucose that triggers hypoglycemia. This right is
especially true if insulin is not adapted to the exercise program.
METABOLISM AND NUTRITION MODULE
16th Group
68
Prevention: for diabetic ketoacidosis, the most important aspect of
treatment is prevention, this form of monitoring of blood glucose levels
carefully and diet, especially on the sata-time stress or illness. If present,
then the diabetic ketoacidosis treated with insulin and measures for
balancing fluid and electrolytes.
Fluid: nonkelotik hiperglikemik hyperosmolar coma treated by giving
fluids in bulk and slow correction of potassium deficit. This incident can
be prevented by good diet control.
Pharmacological interventions that can be considered to be given to
patients with diabetes are antihypertensive medications. Anti-hypertensive
medications have been proven to reduce hypertension in patients with
diabetes and kidney disease awitan slow.
Replacement of the island of Langerhans cells: recent advances in the
techniques of replacement cells of Langerhans islands enables more than
3000 people worldwide were treated with the island of Langerhans cell
transplantation. Treatment in this manner gives hope for diabetes cure in
the future.
Insertion of genes for insulin: is currently also being carried out
preliminary experiments designed to allow insertion of the insulin gene to
type 1 diabetes. In future, this procedure is to provide hope for healing
diabetes, compared with drug therapy.
METABOLISM AND NUTRITION MODULE
16th Group
3.2 ANALYSIS
69
A woman came with problems of her drowsiness and her tingling. In order
to get the diagnosis and the possible patophysiology of her problems, series of
anamnestic question, physical examination, and laboratory test should be done
Anamnesis
Age : 41 years
Marital status : Married, have 1 child
Address : Kupang Indah Surabaya
Job : Housewife
She has tingling since 1 month ago, all the time and progressive.
She often fell sleepy.
She often wakes up at night for micturing.
She losses 3 kg of her weight.
Diabetes : unknown
Hypertension : disputed
Family history :
Her father dead from complication
Her eldest sister dead in 40th years old with a wound in her leg which
cannot be healed and nasty smell
METABOLISM AND NUTRITION MODULE
16th Group
70
She hasn’t received any treatments before.
She often feels thirsty and drinks much.
She often feel hungry too.
She rarely, practically never, does any sports
Physical Examination
General condition : good
Blood pressure : 120/80 mmHg
Pulse pressure : 80 times/minute
Respiratory Rate : 20 times/minute
Temperature : 37o Celsius
Weight : 89 kg
Height : 157 cm
Waist Circumference : 93 cm
No bad smell in her breath
Inspection :
Cyanosis, Anemia, Icterus = Negative (-)
Ascites = negative (-)
Palpation:
Hepar and Lien cannot be felt
Percussion :
Thorax :
Heart and Lungs = Normal
Laboratory Result
Fasting Glucose : 199 mg/dL
2-h PP Glucose : 317 mg/dL
Triachilglicerol 278 mg/dL
Hemoglobin : 12 g/dL
Creatinin Level : 0,7 mg/dL
METABOLISM AND NUTRITION MODULE
16th Group
71
HDL : 38 mg/dL ; LDL : 94 mg/dL; Total Cholesterol : 171 mg/dl
From the data above, we think of the most possible disease called Diabetes
Mellitus. Diabetes mellitus is a group of metabolic diseases characterized by high
blood sugar (glucose) levels that result from defects in insulin secretion, or action,
or both. Diabetes mellitus, commonly referred to as diabetes was first identified as
a disease associated with "sweet urine," and excessive muscle loss in the ancient
world. Elevated levels of blood glucose (hyperglycemia) lead to spillage of
glucose into the urine, hence the term sweet urine. Normally, blood glucose levels
are tightly controlled by insulin, a hormone produced by the pancreas. Insulin
lowers the blood glucose level. When the blood glucose elevates (for example,
after eating food), insulin is released from the pancreas to normalize the glucose
level. In patients with diabetes, the absence or insufficient production of insulin
causes hyperglycemia. This high blood sugar produces the classical symptoms of
polyuria (frequent urination), polydipsia (increased thirst) and polyphagia
(increased hunger). Besides, there is a losing in the body weight. In this patient,
we found some conditions fit these symptomps.
First, the patient has an increase frequency in urination, especially at night
(polyuria,specifically nocturia). Because of losing many water from the body by
polyuria, the brain will compensate it by making a thirst signal that insist person
to drink more and more (polydipsia), and this patient also often feel thirsty. She
drinks much in order to fulfill her thirst. She often feels hungry too. This is what
we called polyphagia, a condition which someone never gets satisfied with their
intake. This polyphagia may occurs because diabetic patient can’t make much
energy from the glucose so it will force the diabetic patient to eat more in order to
make some energies. She also starts losing her body weight, because of the more
lipolysis and muscle (protein) degradation.
Over time, diabetes can lead to blindness, kidney failure, and nerve
damage. These types of damage are the result of damage to small vessels, referred
to as micro vascular disease. Diabetes is also an important factor in accelerating
METABOLISM AND NUTRITION MODULE
16th Group
72
the hardening and narrowing of the arteries (atherosclerosis), leading to strokes,
coronary heart disease, and other large blood vessel diseases. This is referred to as
macro vascular disease. This kind of damage may occur in the patient above. She
has tingling since 1 month ago. This tingling may come from the damage of the
small vessels which supply nerves which inervates the specific location. The
damage may occur because high blood glucose will make the glucose enters
endothelial cells easier because it doesn’t need any insulin. This damage will
make the nerve supplied by the damaged vessels starving and then damaged as
well. It is well known as neuropathy.
Somehow, patient also complains about her being sleepy easily recently.
This drowsiness may be a result from the fatigued cells and the bad quality of
sleep. Diabetic patient has 2 requirements becoming often sleepy. Because the
glucose can’t enter the cells well, the body will feel weaker because it lacks of
energy. Also, atherosclerosis made by the high glucose in diabetic patient will
make the cells receive oxygen less or we called it (hypoxia). Besides, in diabetic
patient, nocturia and sleep apnea often occur and make the patient has a bad
quality of sleep at night. It will be manifested in her drowsiness at day.
Insufficient production of insulin (either absolutely or relative to the
body's needs), production of defective insulin (which is uncommon), or the
inability of cells to use insulin properly and efficiently leads to hyperglycemia and
diabetes. This latter condition affects mostly the cells of muscle and fat tissues,
and results in a condition known as "insulin resistance." This is the primary
problem in type 2 diabetes. The absolute lack of insulin, usually secondary to a
destructive process affecting the insulin producing beta cells in the pancreas, is
the main disorder in type 1 diabetes. In type 2 diabetes, there also is a steady
decline of beta cells that adds to the process of elevated blood sugars. Essentially,
if someone is resistant to insulin, the body can, to some degree, increase
production of insulin and overcome the level of resistance. After time, if
production decreases and insulin cannot be released as vigorously, hyperglycemia
develops.
METABOLISM AND NUTRITION MODULE
16th Group
73
The Insulin Resistance can be occurred in this patient in some ways.
According to Asia standard, her BMI (36,18 kg/m2) put into the condition of
obesity class II. In addition her waist circumference (93 cm) exceed female’s
waist circumference standard. It is called Central Obesity, and it is very dangerous
to our health. This obesity can increase the possibility to the damage of insulin
receptor in body cells someway. When it happens for a long time, sensitivity of
the body cells toward insulin will be more decrease and finally it is called Insulin
Resistance.
Glucose is a simple sugar found in food. Glucose is an essential nutrient
that provides energy for the proper functioning of the body cells. Carbohydrates
are broken down in the small intestine and the glucose in digested food is then
absorbed by the intestinal cells into the bloodstream, and is carried by the
bloodstream to all the cells in the body where it is utilized. However, glucose
cannot enter the cells alone and needs insulin to aid in its transport into the cells.
Without insulin, the cells become starved of glucose energy despite the presence
of abundant glucose in the bloodstream. In certain types of diabetes, the cells'
inability to utilize glucose gives rise to the ironic situation of "starvation in the
midst of plenty". The abundant, unutilized glucose is wastefully excreted in the
urine.
Insulin is a hormone that is produced by specialized cells (beta cells) of
the pancreas. (The pancreas is a deep-seated organ in the abdomen located behind
the stomach.) In addition to helping glucose enter the cells, insulin is also
important in tightly regulating the level of glucose in the blood. After a meal, the
blood glucose level rises. In response to the increased glucose level, the pancreas
normally releases more insulin into the bloodstream to help glucose enter the cells
and lower blood glucose levels after a meal. When the blood glucose levels are
lowered, the insulin release from the pancreas is turned down. It is important to
note that even in the fasting state there is a low steady release of insulin than
fluctuates a bit and helps to maintain a steady blood sugar level during fasting. In
normal individuals, such a regulatory system helps to keep blood glucose levels in
a tightly controlled range. As outlined above, in patients with diabetes, the insulin
METABOLISM AND NUTRITION MODULE
16th Group
74
is either absent, relatively insufficient for the body's needs, or not used properly
by the body. All of these factors cause elevated levels of blood glucose
(hyperglycemia).
The fasting blood glucose (sugar) test is the preferred way to diagnose
diabetes.
Normal fasting plasma glucose levels are less than 100 milligrams per
deciliter (mg/dl).
Fasting plasma glucose levels of more than 126 mg/dl on two or more tests
on different days indicate diabetes.
A random blood glucose test can also be used to diagnose diabetes. A
blood glucose level of 200 mg/dl or higher indicates diabetes.
When fasting blood glucose stays above 100mg/dl, but in the range of
100-126mg/dl, this is known as impaired fasting glucose (IFG). While patients
with IFG do not have the diagnosis of diabetes, this condition carries with it its
own risks and concerns, and is addressed elsewhere.
We try to compare the patient’s blood glucose level with the standard
itself.
Her fasting plasma glucose are 199 mg/dL and the normal fasting plasma
glucose are less then 100 mg/dL.
Her 2-h PP plasma glucose are 317 mg/dL and it exceeds the normal 2-h
PP plasma glucose which is less than 200 mg/dL.
Those conditions above tell us that this patient truly suffers from
hyperglycemia, which is one of the characteristics of Diabetes Mellitus.
In the first, we think that she is suffered from type 2 Diabetes Mellitus,
because from the anamneses we know that she is 41 years old. In that time, before
we learn more about DM, we think that type 2 DM develop with increasing age
and type 1 DM develop in younger age. After that we get a data that explain about
the onset.
METABOLISM AND NUTRITION MODULE
16th Group
75
“ Although type 1 DM most commonly develops before the age of 30, an
autoimmune beta cell destructive process can develop at any age. It is estimated
that between 5 and 10% of individuals who develop DM after age 30 have type
1A DM. Likewise, type 2 DM more typically develops with increasing age, but it
also occurs in children, particularly in obese adolescents.” (Kasper,2005)
So we should analyze more from other data.
We got a data about the risk factors for type 2 Diabetes Mellitus from Harrison's
Principles Of Internal Medicine, 16th Edition,2005 by Kasper.
In this patient, we find some risk factors for type 2 Diabetes Mellitus in
this patient. The first factor is she is obese (the BMI is about 36,1). Second, she is
habitual physical inactivity. Third, triglyceride level is > 250 mg/dL (278
mg/dL). There is one more risk factor that maybe she have but we aren’t sure
about that. That is she have family history of diabetes. From anamneses we know
that her father dead from complication and her eldest brother dead in 40 th years
old with a wound in her leg which cannot be healed and nasty smell. We think
that her father and her brother had suffered from diabetes, because uncontrolled
diabetes can make complication problem and diabetic patient often have wound
that hard to be healed (ulcer).
METABOLISM AND NUTRITION MODULE
16th Group
3.3 FINAL HYPOTHESIS
76
Miss X , 41 years old, has the symptoms of Diabetes Mellitus Type 2 with
hyperglycemia, dysllipidemia due to the decreasing of sensitivity of insulin
receptor in cells caused by her obesity
METABOLISM AND NUTRITION MODULE
16th Group
3.4 FINAL MIND MAPPING
77
METABOLISM AND NUTRITION MODULE
16th Group
Decompensation of β cell of pancreas
Laboratory results:Fasting Glucose: 199 mg/dL
2-h PP Glucose: 317 mg/dL
Triachilglicerol 278 mg/dL
Hemoglobin: 12 g/dL
Creatinin Level: 0,7 mg/dL
HDL: 38 mg/dL ; LDL: 94 mg/dL; Total Cholesterol: 171 mg/dl
Palpation, percussion, & auscultation :
Ascites (-)Hepar & Lien normal
Obese
Compensated by pancreas to produce more insulin
Anamnesis:Tingling all time since a
month agoWake up at night for micturing
Often feel sleepy
3 kgs weight losses
Family sick: father dead from complication and eldest sister dead in 40 years old with a wound in her leg which can’t be healed and nasty smell
Often feels thirsty and drinks much
Often feel hungry too
Hasn’t received any treatments before
rarely, practically never, does any sports
vital sign examination:Pulse : 80/min
RR : 20/min
Temp: 37 oC
Blood pressure : 120/80 mmHg
Weight: 89 kgs
Height: 157 cms
Waist circumference: 93 cms
Inspections:Cyanosis, Anemia,
Icterus (-)
Ascites (-)
Extremity deformities (-)
High level of blood glucose
Type 2 Diabetes Mellitus
A Female, 41 years old
Examination
High lipotoxic from adipocyte
Sensitivity of insulin receptor is decreased
Other complications:Polyuria, polydipsia, polyphagia, tingling, sleepy, and other progressive complication like atherosclerosis, stroke, etc.
78
CASE MAPPING
METABOLISM AND NUTRITION MODULE
16th Group
High level of blood glucose
Obese
Others factor
Polyphagya
Low level of insulin
Complication of diabetes melitus
High lypotoxic
Large amount of adipocytes
Glucose can not enter into cells with GLUT-4
Blood glucose increase
Decompensation of beta cell of pancreas
Compensated by pancreas to increase the insulin
production
Sensivity of insulin receptor decrease
progressively
Type 2 diabetes mellitus
Sensivity of insulin receptor decreased polydypsea polyuria
Chardiovascular disease
Renal disease
Neuropaty
Other complication
3.6 OBSTACLES
3.5 GROUP OPINION
79
Knowing that this woman has type 2 diabetic diseases which cells unable
to use insulin although insulin is produce, oral glucose-lowering agents can be
given to this woman. oral glucose-lowering agents are subdivided into agents that
increase insulin secretion, reduce glucose production, or increase insulin
sensitivity so it can decrease the level of blood glucose. We also suggest that this
woman should seriously change her habit. She should start to exercise, which
make glucose can be absorbed by the cells like skeleton muscle, etc without
insulin, so it can help the insulin’s receptor activity to fulfill the cell needs for
glucose. And the most important, this woman should have diet. She must be
decrease carbohydrate intake, she should has a struggle to restrain her apatite,
because if she is not change her diet, her glucose level will always be high that
have many risk for her health.
1. We are lack to ask more completely about patient examination so it’s
hard for us in making decision of analysis and final mind-map.
METABOLISM AND NUTRITION MODULE
16th Group
80
2. Difficult for gathering the members of our group because of our
bustle.
3. Since all of us are involved in medical science held by the students of
Airlangga University Medical Faculty, we do not have enough time
to gather and discuss
References
U.S. National Library of Medicine, 2010. Drowsiness. Department of Health and
Human Services. Available at:
http://www.nlm.nih.gov/medlineplus/ency/article/003208.htm (Accessed
on November 6th 2010)
National Institute of Neurological Disorders and Stroke, 2010, Peripheral
Neuropathy Fact Sheet, National Institute of Neurological Disorders and
Stroke. Available at:
http://www.ninds.nih.gov/disorders/peripheralneuropathy/detail_peripheral
neuropathy.htm (Accessed on November 11th 2010)
Pathophysiology Of Diabetes Mellitus, unknown year. Pathophysiology Of
Diabetes Mellitus. [Online] (unknown updated date). Available at:
http://www.pathophysiologyofdiabetesmellitus.com/index.html (Accessed
November 7th 2010)
Unknown author, 2009. Phatophysiology of Diabetes. [internet] Diabetes
Manegement in School Setting. Available at:
http://www.dhss.mo.gov/diabetes/DMOverview.pdf (Accessed on
November 7th 2010)
Mayo Clinic, 2010. Diabetes symptoms: When diabetes symptoms are a concern.
[online] (Updated 12 Oct 2010). Available at:
http://www.mayoclinic.com/health/diabetes-symptoms/DA00125
(Accessed 7 November 2010)
METABOLISM AND NUTRITION MODULE
16th Group
81
Mayo Clinic, 2010. Diabetes symptoms: When diabetes symptoms are a concern.
[online] (Updated 12 Oct 2010). Available at:
http://www.mayoclinic.com/health/diabetes-symptoms/DA00125/NSECTI
ONGROUP=2 (Accessed 7 November 2010)
Hani L. .2010. Lingkar Perut Membesar dan Kegemukan. Available at
http://www.indonesiapower.co.id/index.php?
option=com_content&view=article&id=1145:lingkar-perut-membesar-
dan-kegemukan (Accesed on November 17th 2010)
MedlinePlus. 2010. Type 2 Diabetes – risk factors. A service of the U.S. National
Library of Medicine
National Institutes of Health (Online). Available at:
http://www.nlm.nih.gov/medlineplus/ency/article/002072.htm (Accessed
on Nopember 10th 2010)
International Diabetes Federation. 2010. Complications of diabetes. International
Diabetes Federation (Online). Available at:
http://www.idf.org/complications-diabetes, (Accessed on November 10th
2010)
Chernecky & Berger, 2008, Laboratory Tests and Diagnostic Procedures, 5th
Edition, Missouri: Saunders Elvesier
Brandis, Kerry. 2007. Acid-base Physiology. Availablet at
http://www.anaesthesiamcq.com/AcidBaseBook/ab3_2.php (Accessed on
November 8th 2010)
Davidson, S, et al., 1973. Human Nutritions and Dietetics. Edinburgh: English
Language Book Society.
Robert et al., 2003, Harper’s Illustrated Biochemistry, twenty six edition.USA:
Lange Medical
Lopes et al, 2005. Restless Legs Syndrome and Quality of Sleep in Type 2
Diabetes
Greene et al., 1992, Complications: neuropathy, pathogenetic considerations,
Diabetes Care December 1992 Vol. 15 no. 12. Avalable at:
METABOLISM AND NUTRITION MODULE
16th Group
82
http://care.diabetesjournals.org/content/15/12/1902 (Accessed on
November 11th 2010)
eMedicineHealth, 2010, Diabetes Symptoms. Available at
http://www.emedicinehealth.com/diabetes/page3_em.htm (Accessed
November 17th 2010)
Kasper, Dennis L. et al. eds. 2005. Harrison’s Principles of Internal Medicine 16th
ed. New York: McGraw-Hill Companies
Murray, Robert K. et al. 2003. Harper’s Illustrated Biochemistry 26th ed. New
York: Lange Medical Books
Manaf, A. MEKANISME SEKRESI DAN ASPEK METABOLISME. Available
at http://www.google.co.id/url?
sa=t&source=web&cd=2&ved=0CBkQFjAB&url=http%3A%2F
%2Frepository.unand.ac.id
%2F96%2F1%2FINSULIN__MEKANISME_SEKRESI_DAN_ASPEK_
METABOLISME.doc&ei=cPDjTOrFKYi3cIm6ra0M&usg=AFQjCNGSQ
oXZMYjqnExky-cWrgX8Al_FyQ (Accesed at November 17th 2010)
Direktur Gizi Masyarakat. Direktorat Jenderal Bina Kesehatan Masyarakat.
Departemen Kesehatan RI. 2003. PERAN DIIT DALAM
PENANGGULANGAN DIABETES. Available at
http://www.gizi.net/makalah/Makalah%20Pekan%20DM.PDF (Accesed
on November 17th 2010)
Efendic, et al, 1980, Insulin release, insulin sensitivity, and glucose intolerance,
Proceedings of the National Academy of Sciences. (Online), Vol. 77,
No.12. Available at: http://www.pnas.org/content/77/12/7425.full.pdf
(Accessed at November 11th 2010)
Murray, Robert K.2003.Harper’s Illustrated Biochemistry, Twenty-Sixth Edition.
Lange Medical Books/McGraw-Hill Medical Publishing Division.
Guyton, Hall. 2006. Textbook of Medical Physiology 11th Ed. Missisipi : Elsevier
Inc. p.966 - 967
METABOLISM AND NUTRITION MODULE
16th Group
83
Corwin, Elizabeth (2001). Pathophysiology. Jakarta, EGC Penerbit Buku
Kedokteran
METABOLISM AND NUTRITION MODULE
16th Group
84
EBL and Critical Apraissal
For AnsweringQuestion
Searching Method
Information Type
Validity Importance ApplicabilityFoundation Result Foundation Result Foundation Result
LEARNING ISSUES 1 http://www.nlm.nih.gov/medlineplus/ency/article/003208.htm (Accessed on November 6th 2010)
1Internet
BrowsingDigital Article Yes
Content of information
YesIs it
applicable?Yes
http://www.ninds.nih.gov/disorders/peripheralneuropathy/detail_peripheralneuropathy.htm (Accessed on November 11th 2010)
2Internet
BrowsingDigital Article Yes
Content of information
YesIs it
applicable?Yes
http://www.pathophysiologyofdiabetesmellitus.com/index.html (Accessed November 7th 2010)
3Internet
BrowsingDigital Idea No
Content of information
YesIs it
applicable?Yes
http://www.dhss.mo.g
3Internet
BrowsingDigital Article Yes
Content of information
YesIs it
applicable?Yes
METABOLISM AND NUTRITION MODULE
16th Group
CRITICAL APPRAISAL
85
ov/diabetes/DMOverview.pdf (Accessed on November 7th 2010)http://www.mayoclinic.com/health/diabetes-symptoms/DA00125 (Accessed November 7th 2010)
4Internet
BrowsingDigital Idea No
Content of information
YesIs it
applicable?Yes
http://www.mayoclinic.com/health/diabetes-symptoms/DA00125/NSECTIONGROUP=2 (Accessed November 7th
2010)
4Internet
BrowsingDigital Idea No
Content of information
YesIs it
applicable?Yes
http://www.indonesiapower.co.id/index.php?option=com_content&view=article&id=1145:lin
5 Internet Browsing
Digital Idea No Content of information
Yes Is it applicable?
Yes
METABOLISM AND NUTRITION MODULE
16th Group
86
gkar-perut-membesar-dan-kegemukan (Accesed on November 17th 2010)http://www.nlm.nih.gov/medlineplus/ency/article/002072.htm (Accessed on Nopember 10th 2010)
6Internet
BrowsingDigital Article Yes
Content of information
YesIs it
applicable?Yes
http://www.idf.org/complications-diabetes, (Accessed on November 10th 2010)
7Internet
BrowsingDigital Article Yes
Content of information
YesIs it
applicable?Yes
Laboratory Tests and Diagnostic Procedures, 5th Edition
8,9,10,11 eBook Digital Textbook YesContent of information
YesIs it
applicable?Yes
http://www.anaesthesiamcq.com/AcidBaseBook/
12 Internet Browsing
Digital Idea No Content of information
Yes Is it applicable?
Yes
METABOLISM AND NUTRITION MODULE
16th Group
87
ab3_2.php (Accessed on November 8th 2010)
Human Nutritions and Dietetics
13Borrowed from the library
Textbook Article YesContent of information
YesIs it
applicable?Yes
LEARNING ISSUES 2
Harper’s Illustrated Biochemistry, twenty six edition
1,4,7Personal Inventory
Textbook Textbook YesContent of information
YesIs it
applicable?Yes
Restless Legs Syndrome and Quality of Sleep in Type 2 Diabetes
1Borrowing from the library
Textbook Article YesContent of information
YesIs it
applicable?Yes
http://care.diabetesjournals.org/content/15/12/1902 (Accessed on November 11th
2 Internet Browsing
Digital (PDF)
Journal Yes Content of information
Yes Is it applicable?
Yes
METABOLISM AND NUTRITION MODULE
16th Group
88
2010)Partanen, et al.
1995. Natural
History of
Peripheral
Neuropathy in
Patients with
Non-Insulin-
Dependent
Diabetes
Mellitus. The
NEW
ENGLAND
JOURNAL of
MEDICINE.
(Online), Vol.
333 No. 2.
Available at:
http://www.nej
m.org/doi/pdf/1
0.1056/NEJM19
9507133330203
2 Internet Browsing
Digital (PDF)
Journal Yes Content of information
Yes Is it applicable?
Yes
METABOLISM AND NUTRITION MODULE
16th Group
89
(Accessed on
November 20th
2010)
http://www.emedicinehealth.com/diabetes/page3_em.htm (Accessed November 17th 2010)
3Internet
BrowsingDigital Idea No
Content of information
YesIs it
applicable?Yes
Harrison’s Principles of Internal Medicine 16th ed.
4Using
TextbookText Textbook Yes
Content of information
YesIs it
applicable?Yes
http://www.google.co.id/url?sa=t&source=web&cd=2&ved=0CBkQFjAB&url=http%3A%2F%2Frepository.unand.ac.id%2F96%2F1%2FINSULIN__MEKANISME_SEKRESI_DAN_
5 Internet Browsing
Digital (Word)
Article Yes Content of information
Yes Is it applicable?
Yes
METABOLISM AND NUTRITION MODULE
16th Group
90
ASPEK_METABOLISME.doc&ei=cPDjTOrFKYi3cIm6ra0M&usg=AFQjCNGSQoXZMYjqnExky-cWrgX8Al_FyQ (Accesed at November 17th 2010)http://www.gizi.net/makalah/Makalah%20Pekan%20DM.PDF (Accesed on November 17th 2010)
5Internet
BrowsingDigital (PDF)
Article YesContent of information
YesIs it
applicable?Yes
http://www.pnas.org/content/77/12/7425.full.pdf (Accessed at November 11th
2010)
6Internet
BrowsingDigital (PDF)
Article YesContent of information
YesIs it
applicable?Yes
Harper’s Illustrated Biochemistry, Twenty-Sixth
7 Personal inventory
Textbook Text Yes Content of information
Yes Is it applicable?
Yes
METABOLISM AND NUTRITION MODULE
16th Group
91
Edition.Textbook of Medical Physiology 11th
Ed. Missisipi : Elsevier Inc. p.966 - 967
8Personal inventory
Textbook Text YesContent of information
YesIs it
applicable?Yes
Laboratory Tests and Diagnostic Procedures, 5th
Edition
9 eBook Digital Article YesContent of information
YesIs it
applicable?Yes
Pathophysiology 10Borrowing from the library
Text Report YesContent of information
YesIs it
applicable?Yes
METABOLISM AND NUTRITION MODULE
16th Group
SCIENTIFIC PAPER APPRAISAL
Group : 16th group
Title : Natural History of Peripheral Neuropathy in Patients with Non-
Insulin-Dependent Diabetes Mellitus
1. PAPER COMPLETION :
Item Existence (with page)
Title Yes (page 89)
Abstract and or Summary Yes (page 89)
Introduction, Background Yes (page 89)
Method Yes (page 89)
Result Yes (page 89)
Discussion Yes (page 93)
Acknowledgement No
Reference Yes (page 93-94)
Conclusion : the format is not complete
PBL Group 1st Medical Faculty of Airlangga University Medical Ethic and Law Module 2009
2. RESEARCH VALIDITY
Objective: To determine the long-term risk of diabetic polyneuropathy and the factors affecting that risk.
Method: Cross-sectional Study
Item Items found (with page)
Design Cross-sectional study (Page 89)
Hierarchy of Evidence 5
Sample We recruited 133 patients with newly diagnosed NIDDM who were 45 to 64 years old at the time of Table 1Characteristics of the Patients with NIDDM and the Control Subjects at Base Line.diagnosis and 144 randomly selected nondiabetic control subjects in the same age group (Table 1Table 1Characteristics of the Patients with NIDDM and the Control Subjects at Base Line.).2 Both groups were evaluated between May 1, 1979, and December 31, 1981.4 The control subjects were recruited from among 180,000 inhabitants of the county of Kuopio in eastern Finland. At base line, 132 patients with NIDDM and 142 control subjects underwent clinical evaluation and measurement of nerve conduction velocity. Of these, 114 patients with NIDDM (86 percent) and 128 control subjects (90 percent) were evaluated after 5 years of follow-up, and 86 (65 percent) and 121 (85 percent), respectively, after 10 years. (Page 89)
Sample Size We recruited 133 patients with newly diagnosed NIDDM who were 45 to 64 years old at the
PBL Group 1st Medical Faculty of Airlangga University Medical Ethic and Law Module 2009
time of Table 1Characteristics of the Patients with NIDDM and the Control Subjects at Base Line.diagnosis and 144 randomly selected nondiabetic control subjects in the same age group (Table 1Table 1Characteristics of the Patients with NIDDM and the Control Subjects at Base Line.).2 Both groups were evaluated between May 1, 1979, and December 31, 1981.4 The control subjects were recruited from among 180,000 inhabitants of the county of Kuopio in eastern Finland. At base line, 132 patients with NIDDM and 142 control subjects underwent clinical evaluation and measurement of nerve conduction velocity. Of these, 114 patients with NIDDM (86 percent) and 128 control subjects (90 percent) were evaluated after 5 years of follow-up, and 86 (65 percent) and 121 (85 percent), respectively, after 10 years. (Page 89)
Eligibility Criteria We recruited 133 patients with newly diagnosed NIDDM who were 45 to 64 years old at the time of Table 1Characteristics of the Patients with NIDDM and the Control Subjects at Base Line.diagnosis and 144 randomly selected nondiabetic control subjects in the same age group (Table 1Table 1Characteristics of the Patients with NIDDM and the Control Subjects at Base Line.).2 Both groups were evaluated between May 1, 1979, and December 31, 1981.4 The control subjects were recruited from
PBL Group 1st Medical Faculty of Airlangga University Medical Ethic and Law Module 2009
among 180,000 inhabitants of the county of Kuopio in eastern Finland. At base line, 132 patients with NIDDM and 142 control subjects underwent clinical evaluation and measurement of nerve conduction velocity. Of these, 114 patients with NIDDM (86 percent) and 128 control subjects (90 percent) were evaluated after 5 years of follow-up, and 86 (65 percent) and 121 (85 percent), respectively, after 10 years. (Page 89)
Exclusion Criteria -
Sampling Frame Total Sampling
Collecting Data Method The diagnosis of diabetes4 was confirmed by an oral glucose-tolerance test, in which subjects were given 75 g of glucose after a 12-hour overnight fast5; the test was performed in both the diabetic patients and the control subjects. Information about cigarette smoking and the use of alcohol was obtained by questionnaire. (Page 89)
Measurement and or assessment Glucose tolerance was assessed by measuring blood or plasma glucose concentrations (in blood at base line and in plasma at 5 and 10 years) and serum insulin and C-peptide concentrations before and one and two hours after the oral administration of 75 g of glucose. Glucose was measured by the glucose oxidase method (at base line and at the 10-year examination) or the glucose dehydrogenase method (at 5 years).7 Serum insulin was measured by a double-antibody radioimmunoassay (at base line: Novo Industries, Copenhagen, Denmark; at 5 and 10 years:
PBL Group 1st Medical Faculty of Airlangga University Medical Ethic and Law Module 2009
Phasedeph, Pharmacia, Uppsala, Sweden). Serum C peptide was measured by radioimmunoassay (at 5 years: Novo-Nordisk, Copenhagen; at 10 years: 125-I, Incstar, Stillwater, Minn.).7
At all examinations, serum lipid concentrations were determined in samples obtained after the subjects had fasted for 12 hours. Lipoproteins were analyzed enzymatically after ultracentrifugation and precipitation.6,8 Glycosylated hemoglobin was measured at the 5-year and 10-year examinations by liquid cation-exchange chromatography (normal range, 4.0 to 6.0 percent). In the base-line study, albumin was measured by immunodiffusion in 24-hour urine samples (Behringswerke, Mahrburg Lahn, Germany). (Page 89-90)
Instrument The differences in mean values between the groups were analyzed by Student's t-test (two-tailed), the Mann-Whitney U test, or analysis of covariance with control for confounding variables. The categorical variables were analyzed by the chi-square test, McNemar's test, or Fisher's exact test. Time-related changes within a group were analyzed by paired t-tests or the Wilcoxon matched-pairs signed-rank test. Differences in the areas under the serum insulin curve (at base line, 5 years, and 10 years, with insulin-treated patients omitted) between the patients with and without neuropathy were analyzed by repeated-measures analysis of variance (for time of investigation, group, and fasting
PBL Group 1st Medical Faculty of Airlangga University Medical Ethic and Law Module 2009
glucose value at base line and at 5 and 10 years). Serum insulin concentrations were analyzed after logarithmic transformation. The area under the serum insulin curve was calculated by the trapezoidal rule. The Spearman correlation coefficient was calculated for the relation between nerve function and the metabolic variables (glycemic control and serum insulin values). All the data were analyzed with SPSS software (SPSS, Chicago). (Page 91)
Randomization -
Intervention -
Analysis Method Statistical Method (Page 91)
Coherence between design and objective: coherent
Coherence between measurement and instrument used: coherent
Conclusion: valid (ONLY BASED FROM TWO CONCLUSIONS ABOVE)
3. IMPORTANCE
CI : There is no CI.
P : 0.083
If this research were done repeatedly (100x), 8.3 researches will show the same
result as the previous result (by chance).
Conclusion : Because there is no CI, the importance can’t be
measured
PBL Group 1st Medical Faculty of Airlangga University Medical Ethic and Law Module 2009